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SUMMARY
  
SUMMARY 
Hepatocellular carcinoma (HCC) is the second most common cause of cancer related death 
worldwide, only surpassed by lung cancer. Late diagnosis and a high degree of 
chemoresistance lead to a poor survival prognosis for HCC patients, with a 5 year survival rate 
of only 5%. The only approved first line therapy for late stage HCC patients is the multityrosine 
kinase inhibitor Sorafenib. Clinical trials confirmed, that Sorafenib treatment led to a survival 
benefit of 3 months, however treatment efficacy is limited by poor response rates, numerous 
adverse effects and evasive cancer cell signaling. Especially the compensatory activation of 
growth factor receptor signaling is a major problem restricting the clinical benefit of Sorafenib. 
Therefore the search for new therapeutic options to improve the efficacy of Sorafenib is of 
great importance.  
Here we investigate the inhibition of cyclin dependent kinase 5 (Cdk5) as a promising 
combination strategy to improve Sorafenib response in HCC. Combination of Sorafenib with 
Cdk5 inhibition (genetic knockdown by shRNA or CRISPR/Cas9 and pharmacologic inhibition) 
synergistically impaired HCC progression in vitro and in vivo by inhibiting both tumor cell 
proliferation and migration. Importantly, these effects were mediated by a novel mechanism 
for Cdk5: A LC-MS/MS based proteomic approach revealed that Cdk5 inhibition interferes with 
intracellular trafficking, a process crucial for cellular homeostasis and growth factor receptor 
signalling. Cdk5 inhibition resulted in an accumulation of enlarged vesicles and respective 
cargos in the perinuclear region, considerably impairing the extent and quality of growth factor 
receptor signalling (Figure 1). Thereby, Cdk5 inhibition offers a comprehensive approach to 
globally disturb growth factor receptor signalling that is superior to specific inhibition of 
individual growth factor receptors.  
In conclusion, Cdk5 inhibition represents an effective approach to improve Sorafenib response 
and to prevent Sorafenib treatment escape in HCC. Notably, Cdk5 is an addressable target 
frequently overexpressed in HCC and with Dinaciclib a clinically tested Cdk5 inhibitor is readily 
available. Thus, our study provides evidence for clinically evaluating the combination of 
Sorafenib and Dinaciclib to improve the therapeutic situation for advanced-stage HCC patients. 
 
 
  
 
Figure 1 – Cdk5 inhibition prevents compensatory activation of PI3K/Akt pathway by interfering 
with intracellular trafficking. (a) The treatment of HCC cells with Sorafenib causes an inhibition of 
VEGFR and its downstream targets RAS and RAF. (b) In turn, this leads to the compensatory activation 
of growth factor receptor signaling, which allows tumor cells to maintain proliferation and migration, 
mediated via the PI3K/AKT pathway. After activation, growth factor receptors have to be trafficked via 
the endosomal system and are either degraded via lysosomes or recycled via endosomes. (c) We 
uncovered that Cdk5 inhibition interferes with intracellular trafficking leading to an increase in vesicle 
size and an accumulation of respective cargos. (d) Thereby an inhibition of Cdk5 prevents the Sorafenib 
induced compensatory activation of growth factor receptors and respective downstream targets and 
enhances the anti-tumor effects of Sorafenib. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
INTRODUCTION
 Introduction 
 
13 
 
1 INTRODUCTION 
1.1 Hepatocellular Carcinoma 
1.1.1 Pathogenesis and Risk Factors 
Even with extensive research in the field of hepatocellular carcinoma (HCC), it still remains 
one of the most common and lethal cancers worldwide.1,2 HCC accounts for one third of all 
cancer related deaths and represents the leading cause of death in liver cirrhosis patients.3 
This is primarily due to high chemoresistance and difficult diagnosis in early stages. Mainly, 
HCC arises on the basis of a manifested chronic liver disease.4 Chronic infections with hepatitis 
B virus (HBV) and exposure to oncogenic substances like aflatoxin B1 are the main cause for 
HCC in eastern Asia and large parts of Africa. The main risk factors in western countries are 
infections with hepatitis C virus (HCV) and alcohol abuse with non-alcoholic fatty liver disease 
and diabetes as minor risk factors.5 The presented risk factors ultimately lead to liver cirrhosis 
which contributes to the development of HCC and is present in 80-90% of HCC patients.6 
The molecular background on which HCC develops is very heterogeneous.7 Mutations of 
various oncogenes and tumor suppressor proteins like p53 are commonly found in HCC tissue 
compared to healthy liver tissue.8 Numerous signaling pathways are altered in HCC, like the 
Wingless (Wnt) signaling cascade, that is known to be associated with the development of 
several cancer types9 and to support HCC progression.10 The diversity of molecular alterations 
complicates the establishment of effective chemotherapy.  
1.1.2 Staging and treatment 
HCC patients are commonly classified according to the Barcelona clinic liver cancer (BCLC) 
staging system or the Child Pugh system (Figure 2).11,12 The determined stage of disease is 
crucial for the treatment strategy and the prognosis is strongly dependent on the gravity of the 
initial liver disease.13 For patients diagnosed with early stage HCC curative treatment options 
like surgical liver resection, orthotopical liver transplantation or radio frequency ablation are 
available.14 Especially liver transplantations result in excellent prognoses for patients, because 
the underlying liver disease is cured in the process.15 However, it is needless to say that the 
demand for donor organs greatly overtakes the supply. Transarterial chemoembolization 
(TACE) is the method of choice for intermediate stage HCC patients.16 Nonetheless, HCC is 
commonly diagnosed at an advanced stage, where curative treatment is no longer feasible.17 
Therapy resistance against conventionally used chemotherapeutics, like DNA damaging 
agents, narrow the options for drug based treatments.18 Therefore patients diagnosed with 
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advanced stage HCC face a poor prognosis with a median overall survival of 6.5-10.7 months. 
The only available treatment option to increase the median overall survival is the multityrosine 
kinase inhibitor Sorafenib, which is considered the first line treatment for unresectable HCC.19 
 
 
Figure 2 – Barcelona Clinic Liver Cancer and Child-Pugh staging system. Adapted from Forner   
et al.20 
1.2 Sorafenib in HCC therapy 
Sorafenib is an orally available multi-tyrosine kinase inhibitor and represents the only approved 
systemic treatment option for advanced HCC (Figure 3).21 Tumor growth and angiogenesis 
are inhibited by targeting Raf, RET, FMS-like tyrosine kinase 3 (FLT3), c-Kit, vascular 
endothelial growth factor receptor (VEGFR) -1, -2 and -3 and platelet derived growth factor 
receptor (PDGFR) α and β.22 Thereby Sorafenib directly targets the Ras/mitogen-activated 
protein kinase (MAPK)/extracellular signaling-regulated kinase (Erk) pathway, which is 
involved in tumor cell proliferation and angiogenesis and is frequently increased in HCC 
(Figure 4).23 
 
 
Figure 3 – Chemical structure of Sorafenib. 
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The clinical efficiency of Sorafenib was evaluated in two large phase III clinical trials, the 
SHARP (Sorafenib Hepatocellular carcinoma assessment randomized protocol) trial, 
conducted in Europe and America, and a similar trial performed in Asia.19,24 Both revealed a 
significant increase in median overall survival as well as time to radiologic progression in the 
Sorafenib group compared to the placebo group. However, the increase in median overall 
survival only amounts to about 3 months, which is a great achievement, but leaves room for 
improvement. In addition, treatment success was restricted by low response rates and severe 
side effects including hand-foot skin reaction, diarrhea and fatigue. These adverse reactions 
often demand for dose reduction or, at worst, a complete termination of treatment.25 Therefore 
various attempts were made to improve the effect of Sorafenib via combinational therapy, 
though with very little success.21  
Hence, the identification of new targets for the treatment of HCC is of substantial importance 
and might be the key to improve the therapeutic effect of Sorafenib. A study conducted by our 
group could show that the cyclin-dependent kinase 5 (Cdk5) is frequently overexpressed in 
HCC tissue and represents a promising drug target. An inhibition of Cdk5 sensitized HCC cells 
for the treatment with conventional chemotherapeutics and we therefore judged Cdk5 as a 
potential candidate to support Sorafenib treatment.26 
 
 
 
 
Figure 4 – Mechanism of action for Sorafenib. 
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1.3 Cyclin Dependent Kinase 5 
Cyclin dependent kinase (Cdk) 5 can be described as an unusual member of the cyclin 
dependent kinase family, a group of serine/threonine kinases controlled by cyclins with major 
influence on cellular progression by regulating multiple steps of the cell cycle.27 Cdk5 however 
is neither regulated by cyclins nor is it involved in cell cycle control, despite sharing 60% 
structural identity with Cdk1 and Cdk2.28   
In the early 1990s, Cdk5 was discovered in neurons and was long thought to be neuron 
specific.29 In the central nervous system (CNS) Cdk5 plays an essential role in neuronal 
development, migration and function.30 The importance of Cdk5 for brain development is most 
likely seen in mice with a knockout of Cdk5 or its activators p35 and p39, which die perinatally 
due to disruption of the neuronal layering throughout the brain.31 Additionally, Cdk5 regulates 
memory processes and learning by influencing synaptic transmission and axon guidance and 
is accountable for mediating drug addiction by affecting dopaminergic signal transmission 
pathways (Figure 5).30,32 
Numerous reports also show that Cdk5 is involved in the development of various 
neurodegenerative diseases.33 The binding of Cdk5 to p25, the truncated form of its activator 
p35, leads to abnormal kinase activity and thus to increased phosphorylation and activation of 
Cdk5 downstream targets. An overactivation of the Cdk5 signaling cascade is related to the 
pathogenesis of Alzheimer’s and Parkinson’s disease.34-36  
1.3.1 Regulation and Dysregulation of Cdk5 
Like other Cdks, Cdk5 is activated by its binding to the respective catalytic subunits, which are 
in the case of Cdk5 not the eponymous cyclins, but the two non-cyclin Cdk5 specific proteins 
p35 and p39.30 The Cdk5 activators share an amino acid homology of 57% and are both 
regulated by transcription and ubiquitin-mediated degradation.28 Notably, despite their 
sequence similarity, the absence of p39 can be compensated by p35, but not vice versa.37 An 
amino-terminal myristoylation motif defines the subcellular distribution and binds p35 and p39 
to the plasma membrane and cytoskeleton and therefore activated Cdk5 is most likely to be 
found in the cell periphery.38 In addition to the interaction with p35/p39, it was believed that a 
phosphorylation of Cdk5 at residue Tyr15, a target domain for the upstream kinases Fyn and 
c-Abelson (c-Abl) increased kinase activity.39,40 However, Kobayashi et al. showed that in 
neuronal cells a phosphorylation of Tyr15 does not influence kinase activity.41 
Cdk5 activity has to be tightly controlled, because aberrant activation and thus 
hyperphosphorylation of downstream targets is associated with the pathogenesis of 
neurodegenerative diseases. For instance, reports indicate that Cdk5 is involved in the 
hyperphosphorylation of the microtubule associated protein tau, which marks a crucial 
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pathological event in Alzheimer’s disease.42 Abnormal activation is primarily caused by the 
binding of Cdk5 to p25, the N-terminally truncated form of p35 generated by calpain-mediated 
proteolytic cleavage.43 Besides a 5-10-fold increase in half-life compared to p35, p25 lacks the 
myristoylation motif, which leads to a mislocalization of the activated Cdk5-p25 complex to the 
wrong intracellular section and therefore to aberrant target phosphorylation (Figure 5).44  
 
 
Figure 5 - Overview of function and dysregulation of Cdk5 in neurons. Adapted from Liebl et   
al.30 
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1.3.2 Function of Cdk5 in Cancer 
Most of the knowledge about Cdk5 stems from the study of neuronal cells. Nevertheless, in 
the last decade it has been shown that Cdk5 also plays a role in non-neuronal tissue.43 Along 
this line Cdk5 has been associated with human cancer progression.45 Accumulating evidence 
is indicating that Cdk5 is expressed in human cancers, where it is linked to increased cancer 
risk and severity.46,47 For instance, increased levels of Cdk5 or its activators p35/p25 correlate 
with advanced cancer stages and poor prognosis in non-small cell lung cancer (NSCLC), brain, 
nasopharyngeal and breast cancer.48-51 Cdk5 was shown to play a key role in the regulation of 
pathways necessary for cancer progression. For example, the retinoblastoma protein (Rb)/E2F 
pathway is activated by Cdk5 in medullary thyroid carcinoma (MTC), thus promoting cancer 
cell proliferation and cell cycle progression.52,53 In prostate cancer, Cdk5 phosphorylates signal 
transducer and activator of transcription 3 (STAT3) and androgen receptor (AR), thereby 
directly contributing to the dysregulation of these pathways and cancer progression.54,55 
Another important aspect of tumor progression is angiogenesis, where new blood vessels are 
generated from pre-existing ones to manage the increased need for oxygen and nutrients of 
solid tumors. The formation of blood vessels is initiated by endothelial cells, where Cdk5 is not 
only expressed but is a key regulator of proliferation and migration.56-58 Therefore, Cdk5 
inhibition has come into focus as a potential strategy to inhibit cancer growth by disturbing 
angiogenesis, thus starving the tumor.  
In keeping with the latter notion, our group could discover a vital role for Cdk5 in HCC.26 Not 
only is Cdk5 overexpressed in HCC tissue compared to healthy liver tissue, it also regulates 
tumor cell survival by influencing DNA damage response. By exploiting the impact of Cdk5 on 
DNA damage regulation with pharmacological inhibitors or genetic downregulation, HCC cells 
could be sensitized to the treatment with DNA damaging agents. By combining Cdk5 inhibition 
with DNA damaging agents, HCC cell proliferation could be inhibited in vitro as well as in vivo. 
However, DNA damaging agents are only approved for the treatment of patients with 
intermediate stage HCC.20 In the therapeutic schedule of advanced stage HCC patients, DNA 
damage inducing agents received little attention up to this point, because high degree of 
treatment resistance limited therapeutic success.  
1.3.3 Pharmacological Inhibition of Cdk5 
Cyclin-dependent kinases are attractive targets for cancer therapy because of their pivotal role 
in cell cycle regulation and cellular progression.59 As neoplastic cells show a high degree of 
proliferation and cell division, inhibiting growth by arresting cell cycle progression would mean 
a certain specificity for cancer cells.60 Nonetheless, the development of Cdk5 inhibitors started 
on a different basis. The pivotal role of Cdk5 in the pathogenesis of neurodegenerative 
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diseases led to the endeavor to design specific Cdk5 inhibitors.33 Due to the high sequence 
similarity within the Cdk family this presents a difficult task as most inhibitors target a variety 
of Cdks.30 The first Cdk5 inhibitors were Olomoucine and Roscovitine (Figure 6a, b), a 
synthetic derivate of Olomoucine, which target the ATP-binding pocket, an adequately 
conserved domain throughout the Cdk family. Despite having the highest relative selectivity for 
Cdk5, Roscovitine further targets Cdk1, Cdk2 and Erk 1, 2 and 8.61 Nevertheless, Roscovitine 
provided promising preclinical results as an anti-cancer agent, but clinical trials remained 
unconvincing. With the intension of increasing selectivity for Cdk5 for the application in 
neurodegenerative diseases, indolinone D (Boehringer-Ingelheim)62 and 4-amino-imidazoles 
(Pfizer)63 were developed. 
The refinement of Cdk inhibitors led to the development of Dinaciclib (Figure 6c), a novel 
potent small molecule inhibitor with high selectivity for Cdk 5, 2, 1 and 9 (IC50 = 1, 1, 3 and 
4 nmol/l respectively).64 Recent reports already showed that Dinaciclib revealed promising 
effects in various types of cancer. Especially in hematological malignancies Dinaciclib showed 
encouraging results. Collectively, Cdk5 is a promising target for cancer therapy with a variety 
of inhibitors available, which have already been established in clinical context.  
 
Figure 6 - Structure of Olomucine (a), Roscovitine (b) and Dinaciclib (c). 
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1.4 Aim of the Study 
Background: 
 
• The multikinase inhibitor Sorafenib still represents the only approved first line therapy 
for advanced-stage HCC patients. However, due to low response rates, severe side 
effects, and tumor progression, clinical effectiveness is limited and patients face a poor 
prognosis. So far, new therapies or combination approaches to improve Sorafenib 
failed. 
• Sorafenib treatment is limited by chemoresistance and compensatory activation of 
survival signalling and growth factor receptors signaling 
• Compounds that directly address specific growth factor receptors have failed to 
improve Sorafenib responsiveness 
• Cdk5 is frequently overexpressed in HCC and regulates tumor cell survival by 
influencing DNA damage response 
• Cdk5 inhibition can be used to sensitize HCC cells for the treatment with DNA 
damaging agents 
 
 
The aim of this study was to evaluate if Cdk5 inhibition can be utilized to prevent Sorafenib 
induced treatment escape. Therefore, the functional effects of Cdk5 inhibition in combination 
with Sorafenib on tumor cell proliferation and migration were investigated in vitro as well as in 
vivo. Further, the underlying mechanism behind the sensitizing effect of Cdk5 inhibition was 
elucidated. 
 
 
 
Figure 7 
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2 MATERIALS AND METHODS 
2.1 Materials 
2.1.1 Compounds 
(R)-Roscovitine was obtained from Sigma-Aldrich. Sorafenib was obtained from Enzo Life 
Sciences. Dinaciclib and Gefitinib were obtained from Selleckchem. LGR1407 was kindly 
provided by Libor Havlíček, Isotope Laboratory (Institute of Experimental Botany AS CR, 
Prague, Czech Republic). 
2.1.2  Reagents and Technical Equipment 
Table 1 - Biochemicals, inhibitors, dyes and cell culture reagents 
Reagent Producer 
Bovine serum albumin (BSA) Sigma-Aldrich, Taufkirchen, Germany 
Bradford reagent Roti® Quant Bio-Rad, Munich, Germany 
CellTiter-Blue® reagent Promega, Mannheim, Germany 
Collagen G Biochrom AG, Berlin, Germany 
Complete® Roche Diagnostics, Penzberg, Germany 
CyQUANT® Cell Proliferation Assay Kit Life Technologies, Eugene, USA 
Dimethylsulfoxide (DMSO) Sigma-Aldrich, Taufkirchen, Germany 
Dithiothreitol (DTT) Sigma-Aldrich, Taufkirchen, Germany 
Dulbecco’s Modified Eagle Medium (DMEM) PAA Laboratories, Pasching, Austria 
ECL Plus WB Detection reagent GE Healthcare, München, Germany 
Ethylendiaminetetraacetic acid (EDTA) Sigma Aldrich, Taufkirchen, Germany 
Fetal calf serum (FCS) Biochrom AG, Berlin, Germany 
FluorSave® reagent mounting medium Merck, Darmstadt, Germany 
Glycerol Applichem¸ Darmstadt, Germany 
High-Capacity cDNA Reverse Transcription Kit Applied Biosystems, Waltham, USA 
Hoechst 33342 Sigma-Aldrich, Taufkirchen, Germany 
ibidiTreat µ-slides Ibidi GmbH, Munich, Germany 
L-Glutamine Sigma-Aldrich, Taufkirchen, Germany 
Mayer’s Hematoxylin Solution Sigma-Aldrich, Taufkirchen, Germany 
MEM Eagle Medium PAA Laboratories, Pasching, Austria 
MicroAmp® Fast Optical 96-Well Reaction Plate, 
0.1 mL Applied Biosystems, Waltham, USA 
MicroAmp® Optical Adhesive Film Applied Biosystems, Waltham, USA 
Nitrocellulose membrane (0.2 µM) Hybond-ECLTM, Amersham Bioscience, Freiburg, Germany 
Non-fat dry milk powder Carl Roth, Karlsruhe, Germany 
Page Ruler™ Prestained Protein Ladder Fermentas, St. Leon-Rot, Germany 
Penicillin/Streptomycin 100x PAA Laboratories, Pasching, Austria 
Materials and Methods 
 
23 
 
Reagent Producer 
Phenymethylsulfonyl fluoride (PMSF) Sigma-Aldrich, Taufkirchen, Germany 
Polyacrylamide Carl Roth, Karlsruhe, Germany 
Poly-D-lysine hydrobromide (mol wt 70,000-
150,000) Sigma-Aldrich, Taufkirchen, Germany 
Polyvinylidene difluoride (PVDF) membrane (0.2 
µM) 
Hybond-ECLTM, Amersham Bioscience, 
Freiburg, Germany 
PowerUp™ SYBR® Green Master Mix Applied Biosystems, Waltham, USA 
Primers metabion, Planegg, Germany 
Propidium Iodide Sigma-Aldrich, Taufkirchen, Germany 
Puromycin Sigma-Aldrich, Taufkirchen, Germany 
RNeasy® Mini Kit (250) QIAGEN, Hilden, Germany 
Seahorse XF Glycolysis Stress Test Kit Agilent Technologies, Santa Clara, USA 
Seahorse XFe96 FluxPaks (inc. mini) Agilent Technologies, Santa Clara, USA 
Sodium chloride Carl Roth, Karlsruhe, Germany 
Sodium fluoride (NaF) Merck, Darmstadt, Germany 
Sodium orthovanadate (Na3VO4) ICN, Biomedicals, Aurora, OH, USA 
Sodiumdodecylsulfate (SDS) Carl Roth, Karlsruhe, Germany 
Transwell Permeable Supports (8 µm pore 
polycarbonate inserts) 
Corning Incorporated, New York, NY, 
USA 
Tris Base Sigma-Aldrich, Taufkirchen, Germany 
Trypsin PAN Biotech, Aidenbach, Germany 
Tween 20 Sigma-Aldrich, Taufkirchen, Germany 
 
Table 2 - Technical equipment 
Name Producer 
Axioskop microscope Zeiss, Jena, Germany 
Axiovert 25/200 microscope Zeiss, Jena, Germany 
Canon 450D camera Canon, Krefeld, Germany 
Canon DS 126181 camera Canon, Krefeld, Germany 
ChemiDoc™ Touch Imaging System Bio-Rad Laboratories GmbH 
FACSCalibur Becton Dickinson, Heidelberg, Germany 
TCS SP8 confocal laser scanning microscope Leica Microsystems, Wetzlar, Germany 
Mikro 22R centrifuge Hettich, Tuttlingen, Germany 
Nanodrop® Spectrophotometer PEQLAB Biotechnologie GmbH 
Olympus DP25 camera Olympus, Hamburg, Germany 
Olympus BX41 microscope Olympus, Hamburg, Germany 
QuantStudio™ 3 Real-Time PCR System Applied Biosystems 
Seahorse XFe96 Analyzer Agilent Technologies 
SpectraFluor Plus™ Tecan, Crailsheim, Germany 
Vi-Cell™ XR Beckman Coulter, Fullerton, CA, USA 
xCELLigence System Roche Diagnostics, Mannheim, 
Germany 
Zeis LSM 510 Meta confocal laser scanning 
microscope 
Zeis, Jena, Germany 
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2.2 Cell culture 
2.2.1 Solutions and Reagents 
The following solutions and reagents were used for the cultivation of HCC cells. 
Table 3 - Solutions and reagents for cell culture 
PBS (pH 7.4)  PBS+Ca2+/Mg2+ (pH 7.4) 
NaCl  132.2 mM  NaCl  137 mM 
Na2HPO4  10.4 mM  KCl 2.68 mM 
KH2PO4  3.2 mM  Na2HPO4  8.10 mM 
H2O   KH2PO4  1.47 mM 
  
 MgCl2  0.25 mM 
   H2O   
 
Growth medium  Freezing medium 
DMEM/MEM Eagle 500 ml  DMEM 70% 
FCSgold 
(not heat-inactivated) 
50 ml  FCSgold 
(not heat-inactivated) 
20% 
   DMSO 10% 
 
Trypsin/EDTA (T/E)  Collagen G 
Trypsin  0.05%  Collagen G 0.001% 
EDTA  0.20%  PBS  
PBS      
 
2.2.2 Cell Lines 
HUH7 and Hep3B cells were obtained from Japanese Collection of Research Biorescources 
(JCRB) and ATCC, respectively. RIL175 cells were kindly provided by Simon Rothenfußer 
(Center of Integrated Protein Science Munich (CIPS-M) and Division of Clinical Pharmacology, 
Department of Internal Medicine IV, Klinikum der Universität München). For the cultivation of 
HUH7 and RIL175 DMEM supplemented with 10% fetal calf serum(FCS) was used, while 
Hep3B cells were cultured in MEM Eagle supplemented with 10% FCS. All cells were cultured 
at 37°C with 5% CO2 in constant humidity in an incubator. Before cell seeding, all culture flasks, 
multiwell-plates and dishes were coated with collagen G (0.001% in PBS). 
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2.2.3 Passaging 
When cells reached confluency, they were either subcultured 1:2-1:10 in 75cm2 culture flasks 
or seeded in multiwell-plates or dishes for further experiments. For the detachment of cells, 
they were washed with prewarmed PBS and afterwards incubated with trypsin/ethylene 
diamine tetraacetic acid (EDTA) for 2-3 min at 37°C. Tryptic digestion was stopped by adding 
growth medium. To prepare the cells for plating, trypsin/EDTA was removed by centrifugation 
(1000 rpm, 5 min, 20°C) and replaced by fresh growth medium. 
2.2.4 Freezing and Thawing 
For long term storage, cells were detached as described previously and resuspended in ice-
cold freezing medium (containing 20% FCS and 10% DMSO). Aliquots of 1.5 ml (equal to 
3x106 cells) were transferred into cryovials. After an initial storage at -80°C for 24h, cryovials 
were moved to liquid nitrogen for long term storage. For the thawing process, cryovials were 
warmed to 37°C and the cell suspension was immediately dissolved in prewarmed growth 
medium. Through centrifugation (1000 rpm, 5 min, 20°C) excessive DMSO was removed by 
replacing freezing medium with fresh growth medium. 
2.3 Transfection Experiment – Cdk5 shRNA 
For the transduction of HUH7 and Hep3B cells with Cdk5 shRNA and nt shRNA Cdk5 
MISSION® shRNA Lentiviral Transduction Particles (Vector: pLKO.1-puro; SHCLNV-
NM_004935; Clone ID: (1) TRCN0000021465, (2) TRCN0000021466, (3) TRCN0000021467, 
(4) TRCN0000194974, (5) TRCN0000195513; Sigma-Aldrich) and MISSION® pLKO.1-puro 
Non-Mammalian shRNA Control Transduction Particles (SHC002V; Sigma-Aldrich) as a 
control were used according to the manufacturer’s protocol. Both cell lines were transduced 
with a multiplicity of infection (MOI) of one. Successfully transduced cells were selected by 
adding 2µg/ml puromycin to the medium. After the initial selection, puromycin concentration 
was reduced to 1µg/ml for further cultivation to ensure the stable transfection with Cdk5 and 
nt shRNA. Through Western Blot analysis the most efficient and well tolerated clones were 
selected. 
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2.4 Genome Editing Using the CRISPR/Cas9 System 
2.4.1 DNA Isolation and Guide RNA Design 
For the knockout of Cdk5 in murine RIL175 cells the CRISPR/cas9 system was used as 
described previously.65 We decided to introduce an InDel-mutation into exon 2 of the Cdk5 
gene. Genomic DNA was isolated from wild-type RIL175 cells using the QuickExtract DNA 
extraction solution according to the manufacturer’s protocol. The genomic region of interest 
was amplified with the appropriate primers (Table 4) via PCR by using the Phusion® high 
fidelity DNA polymerase kit as described by the manufacturer. Correct amplification was 
checked by agarose gel electrophoresis (2% agarose in Tris/Borate/EDTA buffer, 150 V, 
45 min). Sequencing services were provided by Eurofins Genomics GmbH 
(Ebersberg, Germany).  
 
Table 4 - Sequencing primers 
Name Sequence 
Cdk5_PCR_F 5’- CTTCCTGCATTTCTCGTCCC-3‘ 
Cdk5_PCR_R 5’- CTACAACATGCAAGGGGGTA-3’ 
Cdk5_Sequencing_F 5’- GAGTTTATGGCAGATTCTCC-3’ 
 
For the generation of single guide RNAs (sgRNAs) the CRISPOR-Tefor online designing tool 
was used as described previously.66 The three top-ranked sgRNAs were used for further 
experiments (Table 5).  
 
Table 5 - sgRNA sequences/cloning oligomers 
Name Sequence 
Cdk5_sgRNA1_top 5’-CACCGTTGTGGCTCTGAAGCGTGTC-3’ 
Cdk5_sgRNA1_bottom 5’-AAACGACACGCTTCAGAGCCACAAC-3’ 
Cdk5_sgRNA2_top 5’-CACCGGCTCTGAAGCGTGTCAGGC-3’ 
Cdk5_sgRNA2_bottom 5’-AAACGCCTGACACGCTTCAGAGCC-3’ 
Cdk5_sgRNA3_top 5’-CACCGTGTGTTCAAGGCTAAAAACC-3’ 
Cdk5_sgRNA3_bottom 5’-AAACGGTTTTTAGCCTTGAACACAC-3’ 
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2.4.2 Cloning and Transformation of E.coli 
In the next step, the three top-ranked sgRNAs were cloned via the BbsI restriction site into the 
eSpCas9(1.1)-2A-Puro using the T4 DNA ligase protocol provided by the manufacturer (New 
England BioLabs, Frankfurt a.M., Germany). Therefore cloning oligomers were annealed using 
a PCR cycler (5 min at 95°C, ramp down to 25°C) and diluted (1:200 in H2O) (Table 6).  
 
Table 6 - Oligo-Annealing-Mix 
Reagent Volume [µl] 
sgRNA_top (100 µM) 1 
sgRNA_bottom (100 µM) 1 
T4 ligation buffer 1 
H2O 7 
 
eSpCas9(1.1)-2A-Puro was cloned by introducing the T2A-puromycin resistance cassette from 
PX459 into eSpCas9(1.1) via FseI and NotI (both plasmids were a gift from Feng Zhang, 
Addgene plasmids #62988 and #71814, respectively).67 For the insertion of the annealed 
oligomers the desired plasmid (eCas9_Puro2.0, c=464,9 ng/µl) has to be opened with a suited 
restriction enzyme. Therefore a restriction enzyme mix was prepared and incubated at 37°C 
for 30 min (Table 7).  
 
Table 7 - restriction enzyme mix 
Reagent Volume [µl] 
eCas9_Puro2.0 plasmid (150 ng) 0.323 µl 
FD buffer (10x) 1.5 
FD Bpil (restriction enzyme) 1 
H2O Ad 15 
 
For the assembly of annealed oligomers and opened plasmid a ligation mix containing T4 DNA 
ligase was prepared and incubated at RT for 30 min (Table 8). For the removal of not ligated 
plasmid the PlasmidSafe ATP-dependent DNase was used according to the manufacturer’s 
protocol and incubated at 37°C for 30 min and at 70°C for 30 min (Table 9).  Obtained plasmids 
were stored at -20°C before the transformation of E.coli. 
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Table 8 - ligation mix 
Reagent Volume [µl] 
Restricted plasmid 10 
Annealed oligomers (diluted) 2 
T4 ligation buffer (10x) 2 
T4 DNA ligase 1 
H2O 5 
 
Table 9 - PlasmidSafe Exonuclease mix 
Reagent Volume [µl] 
Ligation product 11 
PlasmidSafe buffer (10x) 1.5 
ATP (25 mM) 0.6 
PlasmidSafe Exonuclease 1 
H2O Ad 15 
 
For the replication of plasmid-DNA, competent DH5α-E.coli were transformed with the 
respective sgRNA plasmids. After addition of plasmid-DNA, E.coli were first kept on ice for 
10 min before being heat-shocked at 42°C for 45 s and returned to ice for 2 min. The bacterial 
suspension was then plated on an agar plate with ampicillin and stored at 37°C over night. On 
the next day 3-5 colonies were picked per plasmid and amplified in 5 ml LB (+) medium 
containing 100 µg/ml ampicillin. Plasmids were then isolated by mini-prep using the Qiaprep 
Spin Miniprep kit as described by the manufacturer. Correct insertion and amplification was 
confirmed by restriction analysis (restriction enzyme: Ehel) and sequencing (U6-F-primer: 
5’-GAGGGCCTATTTCCCATGATTCC-3’) before selected plasmids were amplified and 
isolated using the QIAGEN plasmid Maxiprep Kit according to the manufacturer’s protocol.  
2.4.3 Transfection and Evaluation of Genome Targeting Efficiency 
RIL175 cells were cultured in 6-well plates to a confluency of 60-70% before being transfected 
with respective plasmids (sgRNA1, 2 and 3) using Lipofectamine™ 3000 as described by the 
manufacturer. An eGFP-plasmid was used to evaluate transfection efficiency after 24 hours, 
before puromycin (2µg/ml) was added for another 48 hours. After removal of puromycin, cells 
were left to recover until reaching sufficient confluency for the analysis of genome targeting 
efficiency using T7 Endonuclease I according to the manufacturer’s instructions. Cells 
transfected with the sgRNA plasmid with the highest genome targeting efficiency were 
subjected to clonal selection.  
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2.4.4 Clonal Selection and Knockout Verification 
Clonal-density dilution was used to isolate clonal cell lines. Therefore cells were dissociated 
from the transfected wells and adjusted to a cell number of 0.6 cells/well before being seeded 
into 96-well plates. Cell aggregates were separated with a cell strainer prior to seeding. Single 
cell colonies were grown to confluency before DNA and whole cell proteins were isolated to 
check gene knockout via sequencing and Western blot analysis.  
2.5 Western Blot Analysis 
2.5.1 Cell Lysis 
For the cell lysis cells were washed with ice-cold PBS before adding lysis buffer and freezing 
the cells at -80°C. The cells were then scraped off, transferred into Eppendorf tubes and 
centrifuged (14.000 rpm, 10 min, 4°C) in order to remove debris. To ensure equal amounts of 
protein in all samples, protein concentration was measured using Bradford Assay and adjusted 
by adding 1x SDS sample buffer. The samples were then heated at 95°C for 5 min and kept 
at -20°C until Western blot analysis. 
2.5.2 SDS-PAGE 
For the separation of proteins a discontinuous SDS-polyacrylamide gel electrophoresis (SDS-
PAGE) was used, as described by Laemmli.68 Equal amounts of adjusted protein samples 
were loaded on the discontinuous polyacrylamide gels, which consist of a separation and a 
stacking gel, and were separated using a Mini PROTEAN 3 electrophoresis module. To ensure 
the best protein separation the concentration of Rotiphorese™ Gel 30 (acrylamide) in the 
separation gel was adjusted depending on the molecular weight of the proteins of interest. In 
the first step of electrophoresis the proteins were stacked at a current of 100 V for 21 min 
before being separated at 200 V for 45 min in the second step. To evaluate the molecular 
weight of the proteins the received bands were compared to the prestained protein ladder 
PageRuler™ or the Spectra Multicolor High Range Protein Ladder™.  
2.5.3 Tank Electroblotting and Protein Detection 
After separation, the proteins were transferred onto a nitrocellulose membrane by electro tank 
blotting.69 Before usage the membrane was equilibrated with 1x tank buffer for 15 min. After 
equilibration a blotting sandwich (cathode – pad – blotting paper – separation gel – 
nitrocellulose membrane – blotting paper – pad – anode) was prepared and mounted in the 
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Mini Trans-Blot® system, which was filled with 1x tank buffer. The proteins were transferred 
using a constant current of 100 V for 90 min.   
To block the unspecific binding sites, the membrane was incubated in 5% non-fat dry milk 
powder for 2 h before being incubated with the primary antibody overnight at 4°C. The excess 
of primary antibody was washed away in four washing steps with TBS-T, before the incubation 
with the secondary antibody for 2 h at RT. Secondary antibody were HRP-coupled and 
chemiluminescence was detected by adding ECL substrate and analysed with a ChemiDoc 
touch device. 
 
Table 10 - Solutions and reagents for Western blot analysis 
Lysis buffer   5x SDS sample buffer  
Tris/HCl 50 mM  Tris/HCl pH 6.8 3.125 M 
NaCl 150 mM  Glycerol 50% 
Nonidet NP-40 1%  SDS 5% 
Sodium deoxycholate 0.25%  DTT 2% 
SDS 0.10%  Pryonin Y 0.025% 
activated Na2VO4 300 µM  H2O  
NaF 1 mM    
β-glycerophosphate 3 mM    
pyrophosphate 10 mM    
H2O     
add before use:     
Complete® EDTAfree 4 mM    
PMSF 1 mM    
H2O2 600 µM    
 
Separation gel 7.5%/10%/12%/15%  Stacking gel  
 
RotiphoreseTM Gel 30 25%/33%/ 
40%/50% 
 RotiphoreseTM Gel 30 17% 
Tris (pH 8.8) 375 mM  Tris (pH 6.8) 125 mM 
SDS 0.1%  SDS 0.1% 
TEMED 0.1%  TEMED 0.2% 
APS 0.05%  APS 0.1% 
H2O   H2O  
 
 
Materials and Methods 
 
31 
 
Electrophoresis buffer  Tank buffer 
 
Tris 4.9 mM  Tris base 48 mM 
Glycine 38 mM  Glycine 39 mM 
SDS 0.1%  Methanol 20% 
H2O   H2O  
 
Table 11 - primary antibodies for Western blot 
Antigen Product no. Provider Dilution In 
Akt #9272 Cell Signaling Technology 1:1,000 BSA 5% 
actin MAB1501 Millipore 1:1,000 Blotto 1% 
p-Akt (Ser473) #9271 Cell Signaling Technology 1:500 BSA 5% 
p44/42 MAPK (Erk) #9102 Cell Signaling Technology 1:1,000 BSA 5% 
p-Erk (Thr 202/Tyr204) #9106 Cell Signaling Technology 1:1,000 BSA 5% 
Erk #9102 Cell Signaling Technology 1:1000 BSA 5% 
EGFR #2239 Cell Signaling Technology 1:1,000 BSA 5% 
p-EGFR (Tyr 1068) #2234 Cell Signaling Technology 1:1,000 BSA 5% 
Cdk5 AHZ0492 Invitrogen 1:1,000 Blotto 1% 
p-H2A.X #2577 Cell Signaling Technology 1:1,000 BSA 5% 
p62 (Sequestosome 1) #8025 Cell Signaling Technology 1:1000 BSA 5% 
LC3 #4108 Cell Signaling Technology 1:1000 BSA 5% 
LIN28B #4196 Cell Signaling Technology 1:1000 BSA 5% 
 
Table 12 - secondary antibodies for Western blot 
Antibody Product no. Provider Dilution In 
Goat anti-mouse IgG1: 
HRP BZL07046 Biozol 1:1,000 Blotto 1% 
Goat anti-rabbit: HRP 
(H+L) 111-035-144 Dianova 1:1,000 Blotto 1% 
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2.6 Quantitative Real-Time PCR Analysis 
For the isolation of mRNA from cell culture samples the Qiagen RNeasy Mini Kit (Qiagen, 
Hilden, Germany) was used according to the manufacturer’s protocol. Concentration of mRNA 
in each sample was determined with the NanoDrop® ND-1000 spectrophotometer (Nanodrop 
Technologies, Erlangen, Germany). For the creation of cDNA templates out of mRNA by 
reverse transcription the High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems, 
Foster City, CA, USA) was used as described by the manufacturer. The Real-Time-
Polymerase chain reaction was performed with the ABI 7300 Real Time PCR System (Applied 
Biosystems, Foster City, CA, USA) using SYBR Green Master Mix (ThermoFisher Scientific, 
Germering, Germany) and respective primers. Actin was used as a housekeeping gene. In 
order to evaluate changes in mRNA levels the ΔΔCT method was used as described earlier.70 
2.7 Proliferation Assay 
The proliferation of HCC cells was evaluated using the xCELLigence system provided by 
Roche Diagnostics. The respective cell lines were seeded at the given density in 100 µl growth 
medium in equilibrated 16-well E-plates (HUH7: 2,000 cells per well; Hep3B: 4000 cells per 
well). After an initial incubation of 24 h without any compounds, cells were either treated with 
different substances for 72 h or left untreated as a control (4 wells per experimental condition). 
Through impedance measurement, the xCELLigence system evaluates the cell index, a 
dimensionless parameter, which is proportional to the cell number and recorded every hour. 
After normalizing the cell index to the start point of treatment, the doubling time could be 
evaluated by the xCELLigence software. 
Synergism was evaluated using the Bliss independence model.71 Therefore, the Bliss Value 
(BV) was evaluated by comparing the effects of drug A (EA) and drug B (EB) with the effect of 
the combination of both drugs (EAB) according to the following formula: 
 
 =
AB
A + B	 − A × B	
 
 
Synergistic effects were assumed with BV>1, antagonistic effects with BV<1 and additive 
effects with BV=1. 
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2.8 Migration/Invasion Assays 
To examine the migratory ability of HCC cells under the influence of various compounds, cells 
were first seeded into 6-well plates and either left untreated or pretreated with the indicated 
agent for 24 h. After pretreatment cells were trypsinized, centrifuged (1000 rpm, 5 min, RT) 
and resuspended in DMEM or DMEM containing chemotherapeutic agents. 100,000 cells per 
condition were seeded into collagen G coated Transwell® Permeable Supports (8µm pore 
polycarbonate inserts), which were then placed into a 24-well plate containing 700µl DMEM 
(negative control) or DMEM containing 10% FCS per well. Cells were allowed to migrate for 
16 h (HUH7) or 24 h (Hep3B) before being stained with crystal violet. Cells which remained on 
the upper side of the insert were removed with cotton swabs. Cells which migrated through the 
polycarbonate filter were photographed using a Zeiss Axiovert 25 microscope and a Canon 
450D camera. Five pictures of each sample were used to count the number of migrated cells. 
Cell counting was performed by using ImageJ with the particle counter plugin. For the 
evaluation of invasive capabilities the Transwell® Permeable Supports were coated with 
Matrigel to simulate extracellular matrix. 
2.9 Cell Cycle and Apoptosis Analysis 
Cell cycle analysis and evaluation of apoptosis rates was performed as described by Nicoletti 
et al.72 In detail, cells were seeded at a densitiy of 80,000 cells per well into 24 well plates and 
treated with Sorafenib (5µM) for 24, 48 and 72h. After incubation cells were trypsinized, 
washed with PBS and centrifuged (600 g, 4°C, 10 min). Further cells were permeabilized and 
stained by adding fluorochrome solution (FS) containing propidium iodide, to evaluate DNA 
content. After an overnight incubation at 4°C, cells were analysed by flow cytometry on a 
FACSCalibur device. 
The fluorescence intensity, which is indicative for the DNA content of the cells permits to draw 
conclusions about the rate of apoptosis and cell cycle phase. The cell cycle is divided into 
mitosis (M phase) and interphase, which is again subdivided into G1/G0-phase, S-phase and 
G2-phase. Each of these phases is characterized by their DNA content and thereby their 
fluorescence intensity, which results in characteristic histogram plots (Figure 8). In apoptotic 
cells the DNA is fragmented, which results in low fluorescence (sub-G1 peak). For the 
determination of cell populations in different cell cycle phases and the percentage of apoptotic 
cells the FlowJo 7.6 analysis software (Tree Star Inc., Ashland, USA) was used. 
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Figure 8 - Analysis of apoptotic cells and cell cycle 
2.10 Clonogenic Assay 
For the evaluation of long term cell survival, cells were seeded into 6-well plates and treated 
with the respective compounds for 24 h. After the incubation cells were trypsinized and 
reseeded at a density of 10,000 cells per well into a 6-well plate. After an incubation of 7 d, 
viable cells were stained with crystal violet solution for 10min (RT), before being washed with 
distilled water. Bound dye was solubilized by adding 1ml dissolving buffer and the absorbance 
at 550 nm was measured in a plate-reading photometer. Through the ability of a single cell to 
form a colony after treatment, which is indicated by the amount of bound dye, the efficacy of a 
cytotoxic agent can be determined. 
2.11 Immunohistochemistry 
For the evaluation of proliferating cells in tumors derived from nt and Cdk5 shRNA HUH7 cells 
in a xenograft mouse model, 5 µM sections of tumor tissue were used for immunohistochemical 
staining. Therefore the slides were first deparaffinized in xylene for 15 min and rehydrated by 
descending concentrations of ethanol (20 min in 100% ethanol, 20 min in 95% ethanol). 
Thereafter the sections were boiled in sodium citrate buffer (10 mM sodium citrate, 0.05% 
Tween 20, pH 6.0) for antigen retrieval, before endogenous peroxidase was blocked by 
incubation in 7.5% hydrogen peroxide for 10 min. Between the individual steps the slides were 
washed two times with PBS. As an indicator for proliferating cells the primary antibody for Ki67 
was applied in a dilution of 1:100 in PBS for 1 h at room temperature. The Vectastain® 
Universal Elite ABC Kit was used for antibody detection according to the manufacturer’s 
protocol and AEC was used as a chromogen. The slides were then counterstained with 
hematoxylin for 1 min before being washed with distilled water. The sections were embedded 
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in FluorSave™ Reagent mounting medium and covered with glass coverslips. Images were 
collected with an Olympus BX41 microscope and an Olympus DP25 camera. 
2.12 Immunostaining 
2.12.1 Colocalization 
For immunostaining experiments nt and Cdk5 shRNA HUH7 cells were seeded into 8-well 
ibiTreat µ-slides. Cells were then washed with ice-cold PBS+ Ca2+/Mg2+ once and fixed in 4% 
paraformaldehyde for 15 min, before being washed with PBS once. In order to permeabilize 
the cells 0.2% Triton X-100 was applied for 20 min. Unspecific antibody binding sites were 
blocked by incubation with 0.2 % BSA in PBS for 20 min. Afterwards cells were incubated with 
primary antibodies against EGFR and EEA1 for 1 h. Thereafter cells were washed with PBS 
and incubated with Alexa Fluor® 488 and 546 secondary antibodies together with 5 µg/µl 
Hoechst 33342 in PBS containing 0.2% BSA for 30 min. Each well was then covered with 
FluorSave™ reagent mounting medium and glass coverslips. Images were taken with a Leica 
SP8 confocal laser scanning microscope.  
2.12.2 EGFR surface localization 
For the analysis of EGFR localized exclusively at the cell surface, nt and Cdk5 shRNA HUH7 
cells were seeded into 8-well ibiTreat µ-slides and treated with Sorafenib as indicated. After 
incubation cells are immediately put on ice and incubated with a primary antibody targeting the 
extracellular domain of the EGFR (1:150, Calbiochem, GR01) for 1 h at 4°C. After antibody 
staining cells were washed twice with ice-cold PBS and fixed in 4% paraformaldehyde for 8 
min on ice. Thereafter cells were washed with PBS and incubated with Alexa Fluor® 488 
secondary antibody together with 5 µg/ml Hoechst 33342 in PBS containing 0.2% BSA for 30 
min. Each well was then covered with FluorSave™ reagent mounting medium and glass 
coverslips. Images were taken with a Leica SP8 confocal laser scanning microscope. 
2.12.3 EGF Uptake and Chase 
In order to analyze the uptake of EGF into the cell and its subsequent elimination via 
degradation and recycling, nt and Cdk5 shRNA cells were seeded in 8-well ibiTreat µ-slides 
and treated with 100 ng/ml EGF Rhodamine for various time points. In the chase experiments, 
EGF Rhodamine was removed after 30 min of incubation, cells were washed twice with 
prewarmed PBS and incubated for various time points in medium without FCS. After incubation 
and chase, cells are immediately put on ice, washed twice with ice-cold PBS and incubated 
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with acid wash solution (acetic acid 0.2M, NaCl 0.5M, pH 2.0) for 5 min to remove excessive 
EGF. Cells were then washed with PBS twice and fixed in 4% paraformaldehyde. Thereafter 
cells were incubated with 5µg/ml Hoechst 33342 in PBS containing 0.2% BSA for 30 min. Each 
well was then covered with FluorSave™ reagent mounting medium and glass coverslips. 
Images were taken with a Leica SP8 confocal laser scanning microscope. 
2.12.4 Live Cell Imaging/Time Lapse Microscopy 
nt and Cdk5 shRNA HUH7 cells were seeded in 8-well ibiTreat µ-slides at a density of 5 x 104 
and transfected with either EGFR-GFP (a gift from Alexander Sorkin, Addgene plasmid 
#32751), pLenti-MetGFP (a gift from David Rimm, Addgene plasmid #37560) or Alpha 5 
integrin-GFP (a gift from Rick Horwitz, Addgene plasmid #15238) using DharmaFECT 1 
transfection reagent (ThermoFisher Scientific, Waltham, MA). Cells were imaged using a Leica 
SP8 confocal laser scanning microscope. Frames were taken every 0.75 s for a total of 10 min. 
For the quantification of vesicle size two types of objects have been considered: small vesicles 
(present in both conditions) and “ring shaped” vesicles (present only in Cdk5 shRNA HUH7 
cells). The ParticleSizer Plugin of Fiji after background removal is used to recognize the small 
vesicles, while a Circular Hough Transform based algorithm implemented by the Matlab 
imfindcircles function is used to recognize the “ring shaped” vesicles only in the Cdk5 
knockdown condition after background removal. If the two kinds of vesicles are overlapping 
only the donut shaped ones will be considered. 
2.13 Proteomic Analysis via LC-MS/MS 
2.13.1 Stimulation 
Cells were seeded at a density of 0.35*106 cells per well into 6-well plates and stimulated with 
Sorafenib (0.5 µM, 5 µM, 24 h). After incubation cells were washed five times with PBS and 
detached with trypsin/EDTA as described in Passaging. To remove excessive trypsin/EDTA 
cells were centrifuged (1000 rpm, 5 min, 4°C). Cell pellets were resuspended in 100 µl ice-cold 
PBS and stored at -80°C until further processing. 
2.13.2 Sample Processing 
Per 1*105 cells 20 µl of 8 M urea / 0.4 M NH4HCO3 was added. Cells were lysed using an 
ultrasonic device (Sonoplus GM3200 with BR30 cup booster, Bandelin, Berlin, Germany) 
applying 10,000 kJ. For further homogenization, samples were centrifuged through QIA-
Shredder devices (Qiagen, Hilden, Germany). Protein concentrations were determined by 
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Bradford assays and adjusted to 0.6 mg/ml with 8 M urea/0.4 M NH4HCO3. To cleave bisulfide 
bonds, 25 µg of total protein was incubated with DTE at a concentration of 4.5 mM for 30 min 
and free sulfhydryl residues were blocked with iodoacetamide (final concentration 10 mM) for 
30 min in the dark. After dilution with water to a concentration of 1 M urea, 0.5 µg porcine 
trypsin (Promega, Madison, WI, USA) was added and incubated overnight at 37 °C. 
2.13.3 Liquid-Chromatography Mass Spectrometry 
Chromatography of peptides was performed on an EASY-nLC 1000 chromatography system 
(Thermo Scientific, Waltham, MA, USA) coupled to an Orbitrap XL instrument (Thermo 
Scientific). 2.5 µg of peptides diluted in 0.1 % formic acid (FA) were transferred to a trap column 
(PepMap100 C18, 75 µm x 2 cm, 3 µm particles, Thermo Scientific) and separated at a flow 
rate of 200 nL/min (Column: PepMap RSLC C18, 75 µm x 50 cm, 2 µm particles, Thermo 
Scientific) using a 260 min linear gradients from 5 % to 25 % solvent B (0.1 % formic acid, 100 
% ACN) and a consecutive  60 min linear gradient from 25 % to 50 % solvent B. For data 
acquisition, a top five data dependent CID method was used. 
2.13.4 Proteomic Data Processing 
For the quantitative analysis of the data obtained from the mass spectrometry screen the 
MaxQuant and Perseus software packages (provided by Max Planck Institute of Biochemistry, 
Munich) were used. 
2.14 Glycolysis Stress Test 
Nt and Cdk5 shRNA HUH7 cells were seeded at a density of 1.5 x 104 into a XFe96 microplate 
and grown for 24 h prior to Sorafenib treatment (0.5 µM, 5 µM, 24 h). The Seahorse Glycolysis 
Stress Test Kit was used in combination with the Seahorse XFe96 Analyzer (Agilent 
Technologies, Santa Clara, CA) as described by the manufacturer. Results were normalized 
to DNA content measured with CyQuant® GR dye solution (ThermoFisher Scientific, Waltham, 
MA) according to the manufactures protocol. Data analysis was performed with Wave 2.3.0 
software and Seahorse XF Glycolysis Stress Test Report Generator (Agilent Technologies, 
Santa Clara, CA). 
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2.15 Human HCC Microarrays 
Tissue microarrays (TMA), containing human HCC samples and matched surrounding non-
tumor tissue were produced. Tissue staining and histological scoring was performed by 
Prof. Dr. Doris Mayr and Dr. Veronika Kanitz (Institute of Pathology, Ludwig-Maximilians 
Universitiy, Munich). The TMAs included 115 patients which had been treated with liver 
transplantation or partial hepatectomy at the University Clinic Munich Großhadern between 
2008 and 2013. The formalin-fixed, paraffin-embedded blocks were cut into 2 mm thick slices 
and mounted on SuperFrost Plus microscope slides (Menzel Gläser, Braunschweig, 
Germany). After deparaffinization and rehydration all slides were Hematoxilien-Eosin stained 
in a standard manner (Vector Laboratories, Burlingame, CA, USA). Several blank-slides were 
set aside for immunohistochemical stainings.  
Staining for EGFR was performed by using a Ventana Benchmark XT autostainer using the 
XT UltraView diaminobenzidine kit (Ventana Medical Systems). The Ventana EGFR-antibody 
clone 3C6 (ready to use) was used.  
EGFR-staining of the TMA section was assessed using the immunoreactive score as 
described73: 0 – absent; 1-4 –weak; 5-8 – moderate; 9-12 – strong expression. 
Images were obtained with a digital network microscope Leica DMD108 (Leica Biosystems 
Nussloch, Germany). 
2.16 In vivo Experiments 
All experiments were performed according to German legislation of animal protection and 
approved by the local government authorities (animal test request number: 55.2-1-54-2532-
22-2016). All in vivo experiments were performed by M. Ulrich, C. Atzberger and K. Loske. 
2.16.1 Ectopic Tumor Model 
20 female SCID „CB17/lcr-PrkdcSCID/lcrlcocrl” mice, six weeks old, purchased from Charles 
River, were used. For the implantation of tumors, nt and Cdk5 shRNA HUH7 cells were 
cultured to confluency of about 70% before being harvested as described in (Passaging) and 
3.3*106 cells in 100 µl PBS were injected into the flank of SCID mice. The animals were 
checked regularly for tumor progression and tumor volume was evaluated using a digital 
measuring slide to measure the three parameters, length (a), width (b) and height (c). The total 
volume was determined by the formula a*b*c*π/6 (with π/6 as a correction factor for tumor 
shape). Sorafenib was injected intraperitoneally (100 µl, solvent: 5% DMSO, 10% Solutol, 85% 
PBS). Therefore mice were fixed by hand and turned to allow access to the ventral side, before 
the solution was administered with a 25 G needle. Treatment with Sorafenib was started ten 
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days after implantation with 10 mg/kg/d Sorafenib injected daily for seven days. 18 days after 
the implantation all mice were sacrificed through cervical dislocation. An exponential growth 
model was used to model tumor volume, where the tumor volume at a given time t (N(t)) is a 
function of the starting volume N(0), the time of growth t and of the growth rate α: N(t) = N(0) 
x expαxt. Modelling was performed using a non-linear mixed effects modelling with the software 
NONMEM 7.3. 
2.16.2 Dissemination Assay - Dinaciclib 
20 female C57BL/6 albino “C57BL/6BrdCrHsd-Tyrc” mice, six weeks old, purchased from 
Envigo, were used. The mice were pretreated intraperitoneally with 10 mg/kg Dinaciclib or 
solvent (5% DMSO, 10% Solutol, 85% PBS) three times (48, 24, and 0.5 hours) before cell 
injection. We intravenously injected 2 x 105 Ril175-luc cells into the tail vein and imaged the 
mice after intraperitoneal injection of 6 mg luciferin/mouse on day three after the cell injection 
using the IVIS Lumina system (PerkinElmer). The tumor signal per defined region of interest 
was calculated with the Living Image 4.4 software (Caliper Life Sciences) as 
photons/second/cm2 (total flux/area). 
2.16.3 Dissemination Assay – Cdk5 KO 
20 female C57BL/6 albino “C57BL/6BrdCrHsd-Tyrc” mice, six weeks old, purchased from 
Envigo, were used. We intravenously injected 2 x 105 Ril175-luc cells (either wild-type or Cdk5 
KO) into the tail vein and imaged the mice after intraperitoneal injection of 6 mg luciferin/mouse 
on day three after the cell injection using the IVIS Lumina system (PerkinElmer). The tumor 
signal per defined region of interest was calculated with the Living Image 4.4 software (Caliper 
Life Sciences) as photons/second/cm2 (total flux/area). 
2.17 Statistical Analysis 
All listed experiments were conducted at least three times unless otherwise indicated in the 
figure legends. The given data is presented as mean ± SEM and statistical significance was 
considered if P≤0.05. The statistical analysis was performed with GraphPad Prism software 
version 5.04 (GraphPad Software, San Diego, USA). 
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3 RESULTS 
3.1 Combination of Cdk5 inhibition and Sorafenib Synergistically 
Decreases HCC Cell Proliferation in vitro and in vivo 
In order to evaluate the effects of Cdk5 inhibition on Sorafenib treatment we used HUH7 and 
Hep3B cells and combined Sorafenib with the established Cdk5 inhibitors Roscovitine and 
Dinaciclib as well as the experimental Cdk5 inhibitor LGR1407.74 Due to strong similarities 
among Cdks, inhibitors often lack specificity and target multiple Cdks. Therefore we used a 
genetic knockdown of Cdk5 via shRNA interference in both cell lines to confirm that our results 
are Cdk5 dependent.  
Proliferation as well as clonogenic survival assays showed that the combination of Sorafenib 
treatment with either genetic knockdown of Cdk5 (Figure 9a, b) or pharmacological inhibition 
(Figure 9c-e) synergistically reduced HCC cell proliferation. For the evaluation of synergism 
two different models, Combination Subthresholding and Bliss Independence, were used.75 In 
both models the combination of Cdk5 inhibition with Sorafenib revealed synergistic effects 
compared to single treatments. Respective Bliss values are indicated in Figure 9. 
This sensitizing effect could also be confirmed in an HCC xenograft mouse model. Mice that 
were subcutaneously injected with Cdk5 shRNA HUH7 cells and treated with Sorafenib 
showed strongly reduced tumor size and weight compared to controls or single treatments 
(Figure 10a). Tumor volume was observed over time and respective data subjected to a non-
linear mixed effects modelling technique, which revealed a synergistic effect of the combination 
of Sorafenib and Cdk5 inhibition resulting in a significantly reduced tumor growth rate (Figure 
10b). The reduced tumor size and decreased tumor growth rate can be attributed to a 
significant reduction of proliferating cells in the tumors, as shown by immunohistochemistry 
staining of Ki67 in tumor sections (Figure 10c).  
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Figure 9 - The influence of Cdk5 on HCC growth in vitro. (a) Proliferation of nt and Cdk5 shRNA 
HUH7 cells after treatment with Sorafenib is shown. Corresponding doubling time is shown. One Way 
ANOVA, Tukey *P<0.05, n=3, Bliss Value = 1.98. (b) Proliferation of nt and Cdk5 shRNA Hep3B cells 
treated with Sorafenib is shown. Corresponding doubling time is shown. One Way ANOVA, Tukey 
**P<0.01, n=3, Bliss Value = 2.27. (c) Proliferation of HUH7 cells treated with either Sorafenib, Dinaciclib 
or a combination of both is shown. Corresponding doubling time is shown. One Way ANOVA, Tukey 
*P<0.05, n=3, Bliss Value = 1.75. (d) Proliferation of HUH7 cells treated with either Sorafenib, LGR1407 
or a combination of both is shown. Corresponding doubling time is shown. One Way ANOVA, Tukey 
*P<0.05, n=3, Bliss Value = 1.46.  (e) Clonogenic survival of HUH7 cells treated with either Sorafenib 
or Roscovitin or a combination of both is shown. One Way ANOVA, Tukey **P<0.01, n=3. 
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Figure 10 - Cdk5 inhibition reduces HCC growth in vivo. (a) Tumors of nt and Cdk5 shRNA HUH7 
cells grown in SCID mice that were either treated with Sorafenib or solvent are shown (n=6). (b) Tumor 
volume over the treatment period of 18 days is shown. Table shows the evaluated growth rates that 
were determined by applying an exponential tumor growth model. (c) Immunostaining of respective 
tumors from (a) for Ki67 (red) and hematoxylin (nuclei, blue) is shown. The bar graph indicates 
proliferating cells evaluated by counting Ki67-positive cells. One Way ANOVA, Tukey ****P<0.0001, 
n=6. 
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3.2 Cdk5 Inhibition Prevents Sorafenib Induced HCC Cell 
Migration 
Aside from the anti-proliferative effect, Sorafenib as well as Cdk5 inhibition significantly 
reduced HCC cell migration (Figure 11a). Strikingly, in the past various reports have shown 
that by targeting angiogenesis tumors gain a higher level of malignancy and invasiveness. 
These observations are often linked to dose reductions and treatment termination, which 
frequently occur under Sorafenib treatment.  
As a matter of fact, our results show that treatment of HUH7 and Hep3B cells with Sorafenib 
in a concentration 10-fold lower than used in the proliferation experiments (0.5 µM) led to an 
overall increase of migration (Figure 11b-f) and invasion (Figure 11g). This increase in motility 
is independent from proliferation as Sorafenib does not influence proliferation in the given 
concentration (Figure 11h). An inhibition of Cdk5, either via genetic knockdown (Figure 11a,b 
and e) or pharmacological intervention (Figure 11c,d and f) reduced the overall 
migration/invasion to a level significantly lower than the control and further prevented the 
Sorafenib-induced increase in migration and invasion.  
The anti-migratory effect of Cdk5 could also be confirmed in two in vivo dissemination assays. 
Firstly, C57BL/6 mice were treated with Dinaciclib daily for 2 days before RIL175 cells 
expressing luciferase were injected into the tail vein. Luminescence measurements three days 
after injection showed, that mice treated with Dinaciclib showed a significantly reduced 
dissemination of tumor cells into the lung (Figure 12a). 
Secondly, we used RIL175 cells with a Cdk5 knockout (Cdk5 KO) generated with the CRISPR-
Cas9 system to confirm that the effect was Cdk5 dependent (Figure 12b). Therefore, either 
RIL175 wild-type cells or RIL175 Cdk5 KO cells were injected into the tail vein of C57BL/6 
mice. After three days, luminescence measurement revealed an even greater effect on 
dissemination by Cdk5 KO compared to Dinaciclib treated mice (Figure 12c). 
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Figure 11 - Cdk5 inhibtion prevents cancer cell migration induced by Sorafenib treatment in low 
concentrations. (a-f) Transwell migration of nt and Cdk5 shRNA HUH7 (a,b), wild-type HUH7 (c,d), nt 
and Cdk5 shRNA Hep3B cells (e) and wild-type Hep3B cells (f) that were pretreated with the respective 
compounds in the indicated concentrations is shown. (g) Invasion of nt and Cdk5 shRNA HUH7 cells 
that were pretreated with Sorafenib is shown. (a-g) Respective pictures of migrated cells are shown 
together with bar diagrams showing the number of migrated cells normalized to the control. One Way 
ANOVA, Tukey *P<0.05, **P<0.01, ***P<0.001, n=3. (h) Clonogenic survival of HUH7 cells treated with 
Sorafenib is shown. t-test *P<0.05, n=3. 
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Figure 12 - Cdk5 inhibition reduces HCC metastasis in vivo. (a) Non-invasive images of tumor 
bearing mice either treated with Dinaciclib or solvent are shown. Bar diagram shows corresponding 
signal intensities. t-test, *P<0.05, n=10. (b) Non-invasive images of tumor bearing mice either injected 
with RIL175 wild-type cells or RIL175 Cdk5 KO cells are shown. Bar diagram shows corresponding 
signal intensities. t-test, *P<0.05, n=10. (c) Western Blot showing the protein levels of Cdk5 in RIL175 
wild-type cells and RIL175 Cdk5 KO cells generated via the CRISPR-Cas method. 
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3.3 The Influence of Sorafenib Treatment and Cdk5 knockdown on 
HCC cells – A Proteomic Evaluation 
A previous study conducted by our group showed that Cdk5 inhibition sensitized HCC cells to 
the treatment with DNA damaging agents by influencing DNA damage response, which 
ultimately led to apoptosis. However, the synergistic effect observed by Sorafenib treatment 
combined with Cdk5 inhibition is not caused by alterations in DNA damage response, as 
indicated by unchanged phosphorylation of the DNA damage marker H2A.X (Figure 13a), or 
apoptosis (Figure 13b). 
 
Figure 13 - Influence of Cdk5 inhibition and Sorafenib on DNA damage and apoptosis. (a) 
Immunoblot of nt and Cdk5-1/4 shRNA HUH7 cells treated with Sorafenib and probed for 
phosphorylated H2A.X is shown. (b) Evaluation of apoptotic cells by flow cytometry in Sorafenib treated 
nt and Cdk5 shRNA HUH7 cells. 
 
To get a clue on how Cdk5 inhibition sensitizes HCC cells for Sorafenib treatment, we decided 
to use a LC-MS/MS based whole cell proteomics approach, where we compared the differential 
expression of proteins caused by Cdk5 knockdown alone or in combination with Sorafenib. In 
total, over 2000 proteins were identified, out of which 52 proteins were significantly influenced 
by Cdk5 knockdown, while 48 proteins were changed in abundance by the combination of 
Cdk5 knockdown and Sorafenib. Significant alterations in protein abundance were indicated 
by a log2-fold change > |0.6| and a P-value<0.05 (Figure 14a, b and Supplementary Figure 
1a, b). Selected protein hits were subsequently analysed on mRNA level using RT-qPCR 
analysis (Supplementary Figure 2a, b).  
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Figure 14 - Proteomic analysis of nt/Cdk5 shRNA HUH7 cells. (a) Table of proteins showing 
alterations of protein abundance (P-value < 0.05; log2-fold change > |0.6|) between untreated nt and 
Cdk5 shRNA control cells together with their respective gene names, x-fold changes (nt shRNA vs. 
Cdk5 shRNA) and P-values. (b) Volcano Plot visualizing the protein hits given in table a.  
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A protein-protein interaction (PPI) network analysis revealed significant interaction enrichment 
between the differentially regulated proteins indicating that they are biologically related (Figure 
15a and Supplementary Figure 1c). A subsequent functional enrichment analysis of the PPI 
network uncovered a modulation of proteins involved in cellular metabolism (Figure 15a). In 
addition, we could detect an accumulation of proteins regulated via intracellular trafficking 
including proteins associated with autophagy like p62 and proteins trafficked via endocytosis 
like integrins and the epidermal growth factor receptor (EGFR) (Figure 15b), hinting at a critical 
role of these pathways in the sensitizing effect of Cdk5 inhibition to Sorafenib treatment. We 
therefore decided to evaluate the importance of each identified pathway. 
 
Figure 15 - Protein-protein interaction analysis. (a) Protein interaction map of protein hits given in 
table a created with string-db.org (protein-protein interaction enrichment P-value: 0.0016). Proteins 
involved in cellular metabolic processes are highlighted in red (false discovery rate: 0.0125). (b) The 
graph shows proteins associated with or regulated by endocytosis that were modulated by Cdk5 
knockdown (x-fold change compared to nt shRNA is displayed). 
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Firstly, we decided to investigate cellular metabolism. Cancer cells critically depend on 
increased metabolic activity to satisfy their elevated energy consumption. A deregulation of 
numerous proteins involved in the regulation of metabolism led to the hypothesis that Cdk5 
negatively influences cancer cell metabolism, thereby increasing the effects of Sorafenib. 
Especially the downregulation of LIN28 as shown by proteomic analysis (Figure 14) and 
confirmed by Western blot analysis and mRNA was of particular interest (Figure 16a, b). LIN28 
is a critical regulator of glucose metabolism and is associated with HCC and liver disease.76 
 
 
Figure 16 – LIN28 expression is reduced upon Cdk5 inhibition. (a) Immunoblot of nt and Cdk5 
shRNA HUH7 cells treated with Sorafenib and probed for LIN28B is shown. (b) mRNA levels of LIN28B 
in nt and Cdk5 shRNA HUH7 cells treated with Sorafenib are shown. One Way ANOVA, Tukey 
***P<0.001, ****P<0.0001, n=3. 
 
As cellular metabolism is certainly not dependent on one protein alone but rather regulated by 
a variety of pathways and proteins we decided to take a wider approach and measured 
glycolysis and oxidative phosphorylation via the Seahorse XFe96 Analyzer. The readout for 
glycolysis is displayed as extracellular acidification rate (ECAR), while oxidative 
phosphorylation is measured via oxygen consumption (OCR). We could show that Sorafenib 
indeed influenced cellular metabolism by reducing ECAR as well as OCR (Figure 17a, b). 
However there was no additional effect induced by Cdk5 inhibition (Figure 17c-e). Therefore 
we concluded that the sensitizing effect of Cdk5 inhibition was not due to impaired metabolic 
activity. 
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Figure 17 - Effect of Sorafenib and Cdk5 inhibition on cellular metabolism. Glycolysis Stress Test 
with nt and Cdk5 shRNA HUH7 cells that were pre-treated with Sorafenib before consecutive exposure 
to D-glucose, oligomycin and 2-DG is shown. ECAR and OCR were recorded using a Seahorse XFe96 
Analyzer and normalized with CyQUANT® GR dye. (a-e) Normalized ECAR (left) and OCR (right) of 
untreated and Sorafenib treated nt and Cdk5 shRNA HUH7 cells are compared. 
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Secondly, an accumulation of p62/Sequestosome1, a marker for proteins destined for 
autophagy, indicated that the autophagic flux was disturbed by Cdk5 inhibition. Cdk5 
knockdown cells displayed a significant upregulation of p62/Sequestosome1 as shown by 
proteomic analysis and western blot analysis (Figure 14 and Figure 18a, b). The disturbance 
in autophagic flux could be confirmed by an increase of the LC3-II/I ratio upon Cdk5 inhibition, 
which is indicative of an accumulation of late autophagosomes and thereby a disturbance of 
the equilibrium between early and late autophagic vesicles (Figure 18a, c). The increase in 
p62/Sequestosome1 and LC3-II/I ratio can either be caused by an increase in autophagy or 
by a degradation block. Therefore an artificial degradation block was applied by using 
Concanamycin A, an inhibitor of vesicle fusion (Figure 18d). The LC3-II/I ratio in nt shRNA 
cells was increased in response to Concanamycin A, while Cdk5 shRNA cells remained 
unaffected, pointing to a degradation block in the autophagic cascade by Cdk5 knockdown 
(Figure 18e, f). Nevertheless, Sorafenib did neither affect p62/Sequestosome1 expression nor 
LC3 conversion. Thus the influence of Cdk5 on autophagic flux is unlikely mediating the 
sensitizing effect towards Sorafenib treatment.  
 
Figure 18 - Cdk5 influences autophagic flux. (a) Immunoblots from nt and Cdk5 shRNA HUH7 cells 
treated with Sorafenib probed with antibodies for p62/Sequestosome1 and LC3 are shown. (b) 
Quantitative evaluation of p62/Sequestosome1 from a is shown. (c) Ratio of LC3-II to LC3-I after 
quantitative evaluation from a is shown. (d) LysoTracker Red staining of nt and Cdk5 shRNA HUH7 
cells after treatment with Concanamycin A (ConcA) is shown. (e) Immunoblot from nt and Cdk5 shRNA 
HUH7 cells treated with Concanamycin A and probed with antibodies for LC3-I/II is shown. (f) Ratio of 
LC3-II/I is shown after quantitative evaluation of immunoblots from e. 
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3.4 Cdk5 Influences EGFR Signaling 
Interestingly, the proteomics screen showed that Cdk5 inhibition induced an upregulation of 
proteins involved in or transported via intracellular trafficking (Figure 15b). This finding 
suggested that Cdk5 inhibition interferes with intracellular trafficking, thereby leading to an 
accumulation of respective cargos. Out of the identified cargo proteins, especially the EGFR 
was of particular interest, as an increase of growth factor receptors levels usually leads to more 
aggressive tumor progression.77 In order to elucidate the controversy between elevated EGFR 
levels on the one hand and growth inhibition on the other hand, we decided to use the EGFR 
as an example to investigate the effect of Cdk5 inhibition and Sorafenib treatment on the 
compensatory activation of growth factor receptors.  
Activation of growth factor signaling including EGF-, IGF-, FGF-, or HGF-signaling in response 
to Sorafenib treatment was described as a mechanism of HCC treatment evasion.78-80 Building 
on these findings our results confirm the compensatory activation of EGFR upon Sorafenib 
treatment. While the Ras/Raf/MEK/ERK pathway was inhibited as shown by decreased 
ERK1/2 phosphorylation, the phosphorylation of the growth factor downstream target AKT and 
EGFR itself was induced by Sorafenib (Figure 19a-c). 
 
Figure 19 - Influence of Cdk5 inhibition on EGFR activity. (a,b) Immunoblots from nt and Cdk5 
shRNA HUH7 cells treated with Sorafenib probed with antibodies for phosphorylated EGFR (p-EGFR), 
EGFR, phosphorylated Erk (p-Erk), Erk, phosphorylated Akt (p-Akt) and Akt are shown. (c) Quantitiative 
evaluations of p-EGFR, p-Erk and p-Akt from a,b are shown. One Way ANOVA, Tukey *P<0.05, n=3.  
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Moreover, we could show that upon Sorafenib treatment the surface levels of EGFR are 
significantly increased, making cells more receptive for an activation of EGFR (Figure 20a, b).  
 
 
Figure 20 - Sorafenib increases surface levels of EGFR. (a) Immunostaining for EGFR with an 
antibody specific to the extracellular domain in nt and Cdk5 shRNA HUH7 cells after Sorafenib treatment 
is shown. (b) Relative evaluation of fluorescence intensity from a is shown. One Way ANOVA, Tukey 
**P<0.01, n=3. 
 
We therefore concluded that HCC cells use an activation of EGFR and PI3K/AKT signaling to 
compensate the Sorafenib induced impairment of the Ras/Raf/MEK/ERK pathway, implying 
that this dysregulation might be responsible for the poor therapeutic response to Sorafenib 
treatment (Figure 21). 
 
Figure 21 - Compensatory activation of EGFR upon Sorafenib treatment. 
 
Importantly, the compensatory activation of the EGFR cascade was prevented by Cdk5 
inhibition. By simultaneously treating cells with Sorafenib and Cdk5 inhibition, an induction of 
EGFR activity and consequently and activation of the PI3K/AKT pathway could be successfully 
avoided (Figure 19). Finally, the EGFR surface levels of Cdk5 knockdown cells remained 
unchanged upon Sorafenib treatment (Figure 20).   
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In order to more solidly confirm the interference with growth factor receptor activity as the 
mechanism mediating the sensitizing effect of Cdk5 inhibition, we investigated the effects of 
Sorafenib together  with the EGFR inhibitor Gefitinib. Combination of Sorafenib and Gefitinib 
resulted in a significant reduction of proliferation similar to the combination of Cdk5 inhibition 
and Sorafenib (Figure 22a). Further we observed an analogous reduction in HCC cell 
migration by Gefitinib (Figure 22b). However, Cdk5 inhibition does not directly target EGFR 
kinase activity and even led to an increase of EGFR protein levels, indicating that Cdk5 
inhibition acts through a mechanism different from conventional growth factor receptor 
inhibitors.  
In summary, this set of evidence confirmed the compensatory activation of growth factor 
receptor pathways as a mechanism for HCC cells to evade Sorafenib treatment and sustain 
proliferative and migratory capacities. Importantly, Cdk5 inhibition can be used to prevent the 
compensatory feedback loop which activates the EGFR, despite not targeting the kinase 
activity of the EGFR directly, suggesting a different mode of action. 
 
 
Figure 22 - Sorafenib and Gefitinib reduce HCC cell proliferation and migration. (a) Proliferation 
of HUH7 cells treated with either Sorafenib, Gefitinib or a combination of both is shown. Corresponding 
doubling time is shown. One Way ANOVA, Tukey *P<0.05, n=3. (b) Transwell migration of wild-type 
HUH7 cells that were pretreated with the respective compounds in the indicated concentrations before 
their ability to migrate was determined by Boyden Chamber assay. Representative pictures of migrated 
cells are shown together with bar diagrams showing the number of migrated cells normalized to the 
control. One Way ANOVA, Tukey ***P<0.001, n=3. 
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3.5 EGFR Expression Is High in Human HCC 
In the clinical practice the assessment of EGFR expression in human tissue is not used as a 
diagnostic marker. However, our results show that EGFR signaling and distribution are 
important targets in HCC impaired by Cdk5 inhibition. A perturbation of these pathways may 
increase the efficacy of Sorafenib and overcome treatment resistance. Therefore we wanted 
to evaluate the clinical relevance of the EGFR in HCC by performing an immunohistochemistry 
staining of a tissue micro-array (TMA) containing HCC tumor tissue of 63 patients treated at 
the university hospital in Munich, Germany between 2008 and 2013. Staining and analysis of 
the HCC-TMA was performed in cooperation with Prof. Dr. med. Doris Mayr and Dr. med. 
Veronika Kanitz from the institute of pathology (LMU, Munich, Germany).  
The evaluation of the TMA showed that expression of EGFR was increased in HCC patient 
tissue compared to healthy liver tissue (Figure 23a). About 63.4% of the patient tissues have 
EGFR positive cells, with 44.4% of tissues showing more than 80% EGFR positive cells 
(Figure 23b) and 44.8% demonstrating intermediate or strong EGFR staining intensity (Figure 
23c). As EGFR staining is no common practice for HCC diagnostic we used the 
immunoreactive score (IRS) for breast cancer tissue as described by Remmele et al. as a 
scoring system.73 The IRS takes the percentage of positively stained cells as well as the 
staining intensity into account revealing that 39.5% of patients show an intermediate or strong 
IRS (6-12), out of which 44% show the highest possible score (Figure 23d).  
Next we tried to find a relation between EGFR expression and patient prognosis by correlating 
percentage of positive cells, staining intensity and IRS with tumor grading, r-classification, 
tumor stage, frequency of recurrence and cause of death. However, due to the size and 
heterogeneity of the observed patient population we could not find any correlation between the 
considered parameters (Supplementary Table 1).  
Still, the outcome of our experiment proposes that the EGFR is frequently increased in human 
HCC and could be accountable for treatment evasion, which can be addressed by inhibiting 
Cdk5.  
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Figure 23 - EGFR expression is high in human HCC. (a) Immunostaining of patient tissue for EGFR. 
Pictures of EGFR expression in HCC tissue (left and middle) and healthy liver tissue (right) are shown. 
(b) Table showing percentage of EGFR positive cells in HCC tissue. (c) Table showing the staining 
intensity of EGFR in HCC tissue. (d) Table showing the immunoreactive score for EGFR in HCC tissue. 
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3.6 Cdk5 Is Essential for Intracellular Vesicle Trafficking 
The previous experiments have shown that the prevention of a compensatory activation of the 
EGFR contributes to the sensitizing effect of Cdk5 on Sorafenib treatment. However, our 
results suggest a mechanism different from direct inhibitors of growth factor activity. In order 
to elucidate how Cdk5 inhibition influences the activation of the EGFR we focused on 
endocytosis, a process crucial for EGFR signaling. After being activated trough ligand binding, 
the EGFR has to be internalized and trafficked through early and late endosomes. The 
signaling is then either terminated by degradation via lysosomes or maintained by recycling 
via recycling endosomes.81  
We used Rhodamine-labeled EGF to analyze receptor internalization, but there was no 
apparent effect of Cdk5 inhibition on the uptake of the EGF/EGFR complex (Figure 24a, b). 
In contrast, a pulse-chase experiment showed that Cdk5 inhibition significantly influenced 
EGFR elimination and led to delayed clearance of internalized receptor/ligand complex (Figure 
24c, d).  
 
 
Figure 24 - Cdk5 inhibition influences EGFR elimination. (a) Images display nt and Cdk5 shRNA 
HUH7 cells that were treated with EGF-Rhodamine for various time points and analysed by confocal 
microscopy. (b) Quantitative evaluation of corrected total cell fluorescence (CTCF) of images from a is 
shown. For each condition 30 cells were analysed. (c) Images show nt and Cdk5 shRNA HUH7 cells 
that were incubated with EGF-Rhodamine before EGF-Rhodamine was removed and cells were chased 
for the given time points. (d) Quantitative evaluation of CTCF of images from c is indicated. One Way 
ANOVA, Tukey *P<0.05, **P<0.01, n=3. 
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These findings suggest that Cdk5 inhibition interferes with a late step of EGFR trafficking, 
which is in line with distinct EGFR clusters in the perinuclear region of Cdk5 shRNA cells 
(Figure 25).  
 
Figure 25 - Cdk5 inhibition leads to an accumulation of the EGFR. Immunostaining for EGFR 
(green), EEA1 (red) and Hoechst33342 (blue, nuclei) from nt and Cdk5 shRNA HUH7 cells are shown. 
Scale bar, 25 µm. 
Next we performed live cell imaging of control and Cdk5 knockdown HUH7 cells expressing 
eGFP-tagged EGFR, to get a detailed insight into the effect of Cdk5 inhibition on endosomal 
trafficking of the EGFR. Analysis of vesicle dynamics and size revealed that vesicle trafficking 
was disturbed by Cdk5 inhibition. In nt shRNA cells there was an equal distribution of small 
EGFR-positive vesicles across the cell moving with high velocity and distinct directionality 
(Figure 26a and Supplementary Video 1). On the contrary, Cdk5 shRNA cells showed a 
significant amount of large, ring-shaped vesicles with impaired motility in close proximity to the 
nucleus (Figure 26a and Supplementary Video 1). Evaluation of vesicle size showed that 
vesicles larger than 0.8 µm2 appear only in Cdk5 knockdown cells (Figure 26b).  
 
Figure 26 – Cdk5 influences EGFR trafficking. (a) Single frames from live cell imaging videos of nt 
and Cdk5 shRNA cells expressing GFP-EGFR are shown. Scale bar, 10 µm. (b) Box plot diagram and 
bar diagram show the distribution of vesicle size comparing nt and Cdk5 shRNA. Mann Whitney, 
****P<0.0001, Chi-squared test, ****P<0.0001. 
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Strikingly, the effect of Cdk5 inhibition seems to affect the whole endocytic system, rather than 
being exclusive to EGFR, as Cdk5 knockdown also modulates size and motility of vesicles 
carrying integrin α5, a model protein for endocytic trafficking, and c-MET, the receptor for HGF 
(Figure 27 and Supplementary Video 2 and 3). Specifically, the HGF-receptor is of significant 
importance in this context, because it belongs to the most prominent and frequently 
dysregulated growth factors in HCC.82 Hence, our results indicate, that several important 
growth factor receptors, which are linked to HCC, can be targeted by inhibiting Cdk5. 
 
Figure 27 - Cdk5 inhibition influences intracellular trafficking.  Single frames from live cell imaging 
videos of nt and Cdk5 shRNA HUH7 cells expressing either GFP-Integrin-α5 or GFP-cMet are shown. 
Scale bar, 25 µm (integrin α5), 10 µm (c-Met). 
 
Taken together, our results indicate that Cdk5 inhibition has a global effect on intracellular 
trafficking by disturbing a late step in endocytosis as well as autophagy. This leads to an 
intracellular accumulation of various cargo proteins, which potentially impairs the extent and 
quality of signaling, with special focus on growth factor receptors. As a result, the inhibition of 
Cdk5 provides a global approach to prevent the compensatory activation of growth factor 
receptors commonly induced by Sorafenib and thereby offers a significant advantage over 
individual growth factor receptor targeting. 
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4 DISCUSSION 
4.1 Sorafenib, the First Line Treatment for HCC 
The treatment of late stage HCC patients radically changed with the approval of the multi-
tyrosine kinase inhibitor Sorafenib in 2008. The first and only approved systemic 
chemotherapeutic agent for late stage HCC increased both median overall survival and time 
to radiologic progression by about three months. However, poor response rates and severe 
side effects overshadowed the therapeutic success of Sorafenib. Since then, various attempts 
have been made to increase the therapeutic effect of Sorafenib. 
4.1.1 Sorafenib-Based Combination Therapies for HCC 
Combining chemotherapeutics to enhance therapeutic success and reduce treatment-related 
toxicities is a common practice in cancer therapy. Along this line, a panel of experts proposed 
a framework of guidelines for the development of clinical studies investigating the combination 
of Sorafenib with other chemotherapeutics in HCC.83 Since then, Sorafenib has been combined 
with fluoropyrimidines (Tegefur/Uracil, 5-Fluorouracil)84,85, anthracyclines (Doxorubicin)86,87 
and mTOR inhibitors (Sirolimus and Everolimus)88. Only the combination with mTOR inhibitors 
showed a remarkable increase in overall survival (40 months), while the other studies failed to 
improve the situation for patients. However, the results of the aforementioned mTOR study 
need to be interpreted with caution, as the study aimed at patients recurring after liver 
transplantation, which makes overall survival and progression free survival difficult to compare 
to other studies. This concern is confirmed in a phase I trial investigating the 
Everolimus/Sorafenib combination in advanced-stage HCC patients, showing a median overall 
survival of only 7.4 months.89 Further, the mentioned combination approaches not only failed 
to reduce therapy related adverse events but caused additional chemotherapy related side 
effects, therefore rendering them unsuitable for routine clinical practice.21 
4.1.2 New First Line Treatments for HCC 
Along with the attempts to increase the efficiency of Sorafenib, several clinical trials were 
conducted to establish a new first line therapy for advanced HCC. However, the results of the 
randomized phase III trials comparing Sorafenib against Sunitinib90, Brivanib91 and Linifanib92 
showed that each drug failed to meet the primary end point of increasing overall survival. The 
search for an effective second line therapy has been similarly un-successful, as Brivanib93, 
Everolimus94 and Ramucirumab95 all failed to show significant influence on patient survival in 
global phase III trials after Sorafenib treatment has failed. 
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Recently, two new promising multityrosine kinase inhibitors, Regorafenib96 and Lenvatinib97, 
came into prospect as treatment options for HCC patients. Regorafenib treatment had 
remarkable impact on overall survival of patients progressing under Sorafenib treatment, thus 
providing the first effective second line therapy.96 Lenvatinib reached overall survival rates 
similar to Sorafenib in a randomized phase III non-inferiority trial in advanced stage HCC 
patients while showing significant improvements in all secondary efficiency parameters, e.g. 
response rate, time to progression and progression free survival.98 Lenvatinib thereby presents 
a reasonable alternative to Sorafenib as a first line treatment. Apart from inhibiting multiple 
tyrosine kinases, the interference with immune checkpoint signaling by targeting the 
programmed cell death protein 1 (PD-1) was discussed as a potential therapy for HCC.99 On 
this basis, Nivolumab, a human monoclonal antibody against PD-1, was evaluated in clinical 
trials and recently approved as a second line therapy for HCC patients progressing under 
Sorafenib treatment.100 However, Sorafenib is still expected to remain the standard of care. 
Therefore it is of paramount importance to search for ways to improve the impact of Sorafenib 
on HCC. 
4.2 Treatment Escape of Sorafenib Is Caused by Compensatory 
Activation of Survival Signaling 
The activation of parallel pathways to evade chemotherapeutic treatment is a common trait of 
cancer.101 The evasion of Sorafenib treatment in HCC is mainly caused by the activation of the 
Ras/Raf/MEK/ERK pathway, the PI3K/AKT/mTOR pathway, histone deacetylases (HDACs), 
as well as growth factor receptors.102 
4.2.1 Sorafenib Leads to an Upregulation of Parallel Pathways 
Sorafenib directly inhibits the activity of the Ras/Raf/MEK/ERK pathway by targeting the Raf 
kinase. However, an inhibition of Raf kinase activity by Sorafenib triggers complementary 
and/or feed-back mechanisms in HCC, which partially restore the activity of ERK, thereby 
reducing the therapeutic impact of Sorafenib.103,104 Along this line, a combination of Sorafenib 
with MEK inhibitors could show some efficacy in preclinical and clinical studies, particularly 
when Ras was mutated.105 Further, increased levels of MAPK14 has been shown to be 
associated with poor Sorafenib response in HCC and inhibition of MAPK14 could restore 
sensitivity to Sorafenib.106 The PI3K/AKT/mTOR pathway has been shown to be playing a 
crucial role in HCC, where it is activated in 30-50% of cases and renders HCC cells less 
sensitive to Sorafenib treatment.107 In keeping with the latter notion, combining Sorafenib with 
PI3K/AKT/mTOR inhibitors showed favorable results in a phase 1/2 study108, while other 
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studies report severe side effects and failure to improve patient survival.89,109 The simultaneous 
inhibition of HDACs along with Sorafenib treatment started out positive with encouraging 
results in preclinical studies, but consecutive clinical trials revealed severe side effects and 
had to be terminated (reviewed in 102). 
4.2.2 Sorafenib Leads to Compensatory Activation of Growth Factor Receptor 
Pathways 
The deregulation of growth factor receptor signaling pathways is commonly observed in 
cancer. High degrees of redundancy lead to an overactivation of one growth factor receptor 
pathway to overcome the malfunction of another pathway, leading to treatment evasion and 
tumor progression, which is often observed in HCC.110 Compensatory activation of growth 
factor receptors results in an overactivation of Ras/Raf/MEK/ERK pathway and the 
PI3K/AKT/mTOR pathway, two pathways with a mutual dependency in HCC.111 Upon 
Sorafenib treatment and thereby an inhibition of the Ras/Raf/MEK/ERK cascade, an activation 
of the PI3K/AKT/mTOR pathway is observed112,113, which is associated with malignancy and 
metastasis.114,115 These findings are in line with our results showing increased HCC cell 
migration and EGFR activation, and subsequent AKT signaling, upon Sorafenib treatment. By 
inhibiting Cdk5 the compensatory activation of the EGFR-AKT axis can be prevented, thereby 
sensitizing HCC cells towards Sorafenib treatment. 
4.3 EGFR Signaling in HCC 
From the family of growth factor receptors the EGFR was the first member to be linked to the 
development of cancer.116 Since then, the role of EGFR in a variety of human malignancy was 
elucidated117, which led to the development of numerous strategies to inhibit EGFR activity 
(reviewed in 118). Our results demonstrate that EGFR expression is high in human HCC tissue. 
This is in line with previous studies showing that EGFR is frequently overexpressed in HCC 
and correlates with metastasis, tumor aggressiveness and poor patient survival.77,119,120 
Therefore, EGFR inhibition was evaluated as a therapeutic option for the treatment of HCC. 
4.3.1 Preclinical Evaluation of EGFR Inhibitors for HCC Treatment 
In preclinical studies the inhibition of EGFR activity with either Erlotinib, Gefitinib or Cetuximab 
showed encouraging results in HCC cell lines.121 The chimeric EGFR-directed monoclonal 
antibody Cetuximab showed a significant growth reduction in p53 wild-type HepG2 cells and 
sensitized p53-mutated HUH7 cells for the treatment with Fluvastatin and Doxorubicin. Growth 
reduction was achieved via an arrest of cell cycle progression by increasing levels of Cdk 
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inhibitors p21 and p27 and elevated levels of apoptosis.122 Treatment with Erlotinib or Gefitinib, 
two small molecule inhibitors of the tyrosine-kinase domain of the EGFR, resulted in reduced 
growth rate, increased apoptosis and cell cycle arrest in human HCC.123,124 By inhibiting MAPK 
and STAT pathway activity, Erlotinib treatment led to an induction of a G1/G0 arrest, an 
increase in pro-apoptotic factors and a decrease in anti-apoptotic factors.125  
Further, both Erlotinib and Gefitnib showed promising results in animal tumor models. In a 
diethylnitrosamine (DEN)-induced HCC tumor model, Erlotinib not only impeded the 
progression of cirrhosis but also prevented the development of HCC.126 Similar to Erlotinib, 
Gefitinib led to a significant reduction of tumor size and metastasis in orthotopic HCC mouse 
models.127 The tumor growth inhibiting effect of Gefitinib could even be enhanced by 
combinational treatment with the cytotoxic agent cisplatin.128  
Taken together, the preclinical results for EGFR inhibition in HCC in vitro as well as in animal 
models established a reasonable basis for further clinical trials. 
4.3.2 Clinical Trials Investigating EGFR Inhibitors in Human HCC 
The inhibition of EGFR was already shown to be effective in other solid tumors like colorectal 
cancer and non-small cell lung cancer.129,130 The efficacy in other solid tumors together with 
the promising preclinical results in HCC and the fact that EGFR is overexpressed in the 
majority of human HCC led to a series of clinical trials for the evaluation of EGFR inhibition as 
a therapeutic strategy in HCC patients. However, EGFR inhibition in patients with HCC only 
achieved modest results. While Lapatinib131 and Gefitinib132 treatment showed no benefits for 
HCC patients, Erlotinib as a single agent resulted in moderate effects.133 Also Cetuximab had 
no effect on HCC progression if applied as a single agent134 and only had minor effects in 
combination with Gemcitabine and Oxaliplatin.135 Erlotinib was also tested in combination with 
the angiogenesis inhibitor Bevacizumab, but failed to achieve any clinical improvements for 
HCC patients.136  
The most promising approach for the use of EGFR inhibitors in HCC was the combination with 
Sorafenib, as a combination of Sorafenib and Gefitinib showed encouraging results in HCC 
xenograft mouse models.78 The combination of Sorafenib and Erlotinib was evaluated in the 
SEARCH (Sorafenib and Erlotinib, a Randomized Trial Protocol for the treatment of Patients 
witch Hepatocellular Carcinoma) trial, the only phase III clinical trial in HCC involving an EGFR 
inhibitor. However, the combination treatment failed to show a significant survival benefit for 
patients.137 The failure of these clinical trials put the specific targeting the EGFR as reasonable 
approach for HCC treatment into doubt. 
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4.3.3 Growth Factor Receptor Signaling in HCC 
The difficulties which arise by targeting a specific growth factor receptor are related to the high 
degree of redundancy in growth factor receptor signaling. The inhibition of an individual growth 
factor receptor frequently leads to a compensatory activation of other growth factor receptors 
and subsequent signaling pathways, ultimately resulting in treatment evasion. In human HCC 
a variety of growth factor receptors is deregulated and targeting a single growth factor receptor 
seems to be insufficient, as shown by several clinical studies. For example, there is 
accumulating evidence that the insulin-like growth factor-1 receptor (IGF1R) and the 
hepatocyte growth factor receptor (HGFR) are involved in the development of HCC.121  
HGFR/c-MET was shown to be overexpressed in advanced HCC tissue and the role in the 
development of HCC was confirmed in mouse models.120,138 The activation of a liver-specific 
inducible MET transgene led to HCC development in transgenic mice, while the deactivation 
decreased tumor size via apoptosis and reduced proliferation, thereby showing the direct 
involvement of c-MET in hepatocarcinogenesis.139 Additionally, previous studies could show 
that phosphorylation of c-MET is mediated via an EGFR dependent pathway suggesting a 
simultaneous inhibition of EGFR and c-MET to increase clinical impact.121,140 Likewise, the 
IGF1R is frequently overexpressed (33% of HCCs) and overactivated (52% of HCCs) in human 
HCC.141 It was shown that EGFR activation was needed for IGF-2 mediated proliferation in 
HCC cells and that parallel inhibition of IGF1R and EGFR had a synergistic effect on HCC 
progression. Interestingly, hepatoma cells used an EGFR dependent pathway to compensate 
IGF1R inhibition underlining the interconnection of the two signaling pathways.142  
Thus, it was thought that combining inhibitors for individual growth factor receptors would 
increase therapeutic efficiency and reduce occurrence of resistance.121 However, the 
application of several specific growth factor receptor inhibitors would also mean combining the 
respective adverse effects, resulting in a severe burden for patients and an increased risk for 
treatment discontinuation due to serious secondary effects. Therefore, this approach is highly 
unlikely to find application in the clinical context. Along this line, targeting several growth factor 
receptors by interfering with a common process during signal activation, rather than inhibiting 
individual kinase activities, would be a more favorable method accompanied by less adverse 
effects.  
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4.4 Cdk5 Interferes with Intracellular Trafficking to Inhibit Growth 
Factor Receptor Signaling 
In this study we suggest targeting Cdk5 as a promising approach to increase the efficacy of 
Sorafenib in HCC. The results presented here provide direct evidence that an inhibition of Cdk5 
enhances the therapeutic effect of Sorafenib by preventing the compensatory activation of 
growth factor receptors. We could confirm that Sorafenib treatment leads to an activation of 
the EGFR/Akt pathway. This compensatory activation could be prevented by Cdk5 inhibition. 
Like many other growth factor receptors, the EGFR pathway critically relies on endosomal 
trafficking.81 In this study, we provided evidence that Cdk5 disturbs endosomal and autophagic 
trafficking causing an accumulation of respective cargos and an enlargement of endosomal 
vesicles, thereby critically interfering with receptor activity. 
4.4.1 Endocytosis and Cancer 
Endocytosis is a crucial mechanism for cells to regulate intracellular homeostasis and to 
communicate with their environment. Cells use endocytic trafficking to internalize ligand-bound 
surface receptors, nutrients, immunoglobulins and a variety of other extracellular molecules.143 
The endocytic circuitries are tightly regulated by the Rab proteins, a family of small GTPases 
which control various processes of the endocytic cascade including formation of vesicles, 
directed movement of vesicles and vesicle fusion.144 The activity of Rab proteins is in turn 
regulated by guanine nucleotide exchange factors (GEFs) which mediate the exchange of 
GDP for GTP and GTPase-activating proteins (GAPs) which initiate GTP hydrolysis.145 
Especially, Rab 5, 7 and 11 play a critical role in surface internalization, vesicle maturation and 
recycling. In the context of surface receptors, endocytosis plays a pivotal role in mediating 
signaling.146 Growth factor receptors are internalized via endosomes after activation and are 
then targeted to different fates via endosomal sorting. The receptor signaling is either 
terminated by degrading the receptor via lysosomes or maintained through recycling to the 
plasma membrane.81  
In recent years evidence accumulated that cancer cells manipulate endocytosis to alter 
intracellular trafficking to their advantage.147 By rerouting endosomal vesicles containing 
growth factor receptors destined for degradation back to the plasma membrane via recycling 
pathways, cancer cells sustain growth factor receptor signaling and avoid receptor 
downregulation.148 The mechanisms used by cancer cells to sustain receptor signaling are 
diverse. In the case of EGFR, activation through EGF mainly leads to receptor degradation via 
lysosomes, while binding to TGF-α favours the recycling route.149 Consequently, tumors 
expressing TGF-α can use autocrine feedback loops to avoid EGFR downregulation. Another 
way to sustain receptor activity is the impairment of ubiquitylation. The binding of ubiquitin 
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significantly influences the fate of internalized cargos and decides between degradation and 
recycling.150 In glioblastoma, EGFR was shown to have an oncogenic deletion mutation 
(EGFRvIII), which leads to hypo-ubiquitylation and thereby to reduced internalization and 
increased recycling.151 Further, receptor fate can be altered at the last stage of intracellular 
sorting. In multivesicular bodies (MVB), endosomal sorting complexes required for transport 
(ESCRTs) proteins are required to deliver ubiquitinylated cargos to lysosomes for 
degradation.152 Studies have shown that a downregulation of ESCRT proteins led to 
substantially reduced degradation of EGFR followed by continued signaling.153,154 Despite 
being the best characterized receptor in this context, these findings are not exclusive to the 
EGFR and affect other growth factor receptors as well.148 Apart from the EGFR, especially the 
IGF-, FGF- and HGF-receptors play a very important role in Sorafenib treatment escape in 
HCC and also critically dependent on endocytic trafficking.79,80 
Another group of proteins that is critically dependent on endocytosis and associated with 
cancer is the integrin family, a group of transmembrane receptors promoting cell-to-
extracellular matrix adhesions. After binding to their extracellular ligand, integrins are 
internalized similar to growth factor receptors and degraded via lysosomes. Similar to growth 
factor receptor trafficking, integrin degradation and recycling is regulated by Rab proteins. 
Cells with a migratory phenotype have to sustain a constant fluctuation of integrins from the 
plasma membrane back to the leading edge of movement (reviewed in 155). Especially for 
highly invasive and motile cancer cells it is imperative to maintain a continuous recycling of 
integrins rather than directing them to degradation. Along this line integrins mediate crucial 
steps in metastatic processes (reviewed in 156). Another important mechanism for cancer cells 
to gain invasive capabilities is the epithelial-to-mesenchymal transition (EMT). Through EMT 
cancer cells lose their epithelial phenotype through the loss of E-cadherin and tight junction 
proteins, and gain mesenchymal traits, characterized by migratory and invasive behavior. This 
is an essential process in the formation of distant metastasis, which is highly dependent on 
and interconnected in endocytic circuitries (reviewed in 157). 
In summary, the endosomal system is commonly hijacked by cancer cells to redistribute 
intracellular cargo and is therefore a promising target for cancer treatment.147 On this basis 
several preclinical studies showed promising anti-cancer effects by interfering with endocytosis 
and thereby gave valuable insights into new opportunities presented by targeting intracellular 
trafficking.158-160 However, these studies used experimental drugs, which are not yet approved 
for the treatment of patients. In this study we suggest targeting Cdk5, a protein with clinically 
evaluated inhibitors ready at hand, as an effective strategy to interfere with intracellular 
trafficking. By inhibiting Cdk5 the incorrect transport and aberrant activation of growth factor 
receptors and integrins can be prevented, thereby impeding both cancer cell proliferation and 
migration.  
Discussion 
 
69 
 
4.4.2 Cdk5 is important for vesicle trafficking 
In cancer cells Cdk5 has not yet been associated with endocytic trafficking, but there is 
evidence for the vital role of Cdk5 in the regulation of endocytosis in the neuronal system.161 
The role of Cdk5 in neurons has been extensively studied and Cdk5 has been established as 
a central regulator of endocytosis in the central nervous system. Cdk5 was shown to play an 
essential role in the endocytosis of clathrin coated vesicles in synapses by cophosphorylating 
the dephosphins amphiphysin I, dynamin I and synaptojanin and thereby enabling vesicle 
fission and formation.161,162 Further, Cdk5 is involved in vesicle and membrane trafficking at 
presynaptic and postsynaptic sites. At presynaptic sites, Cdk5 mediates the release of 
neurotransmitters by regulating the vesicle pool composition and phosphorylating 
neurotransmitter-releasing substrates. At postsynaptic sites, Cdk5 is responsible for the 
phosphorylation of numerous substrates regulating the endocytosis of membrane receptors 
like the N-methyl-D-aspartate (NMDA) receptor (reviewed in 163). Recently, Cdk5 has been 
shown to regulate the Rab8-Rab11 cascade in axon outgrowth by directly phosphorylating 
GRAB, a GEF of Rab8, thus creating a link between Cdk5 and the regulation of Rab proteins.164 
Thus, Cdk5 might regulate the activity of other Rab proteins by a similar mechanism, thereby 
influencing endocytosis and autophagy. This represents an interesting question for future 
research. 
4.5 Dinaciclib, a Clinically Available Cdk5 Inhibitor 
Targeting Cdks is a promising approach in cancer therapy. For example, inhibitors of Cdk4 
and 6, Palbociclib165, Ribociclib166 and Abemaciclib167, are approved for the treatment of 
advanced or metastatic breast cancer in combination with Letrozole. Along this line, Palbociclib 
showed promising results in a preclinical HCC study and could enhance Sorafenib efficacy in 
an HCC mouse model.168 The notion of targeting Cdk5 was based on the involvement in the 
pathogenesis of neuronal diseases like Alzheimer’s and Parkinson’s disease.33 Therefore an 
inhibition of Cdk5 has been a desirable goal and led to the development of a wide range of 
Cdk inhibitors, which are primarily selective for Cdk5. Recently, the role of Cdk5 extended 
beyond the neuronal system169, which led to the evaluation of Cdk5 inhibitors in a variety of 
diseases. Roscovitine was evaluated in phase I and II clinical trials for the treatment of 
advanced solid tumors and non-small cell lung cancer, however with little success. Further the 
small molecule Cdk5 inhibitor AT7519 has been tested in patients with advanced or metastatic 
tumors in a phase I trial and in patients with relapsed or refractory chronic lymphocytic 
leukemia (CLL) and mantle cell lymphoma (MCL) in a phase II trial (reviewed in 170). However, 
the phase II trials in CLL and MCL only revealed mediocre results for AT7519 as a single 
agent.171  
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In this context the role of Dinaciclib in recent clinical history has to be emphasized. Dinaciclib 
is a small molecule Cdk5 inhibitor that offered encouraging anti-cancer effects in combination 
with an acceptable profile of adverse effects in clinical trials. Especially in hematologic 
malignancies Dinaciclib could achieve good results. A phase III clinical trial successfully 
evaluated the efficacy of Dinaciclib as a therapy for chronic lymphocytic leukemia.172 This 
achievement led to the clinical investigation of Dinaciclib for the treatment of other forms of 
leukemia.173 In summary Dinaciclib is expected to have a clinical impact in the foreseeable 
future and in accordance with our study, Dinaciclib offers a promising therapeutic approach to 
limit treatment escape and increase the efficacy of Sorafenib in advanced HCC patients.  
4.6 Conclusion and Outlook 
What are the new findings? 
Cdk5 inhibition is elucidated as a promising approach to improve Sorafenib responsiveness in 
HCC as:  
• Cdk5 inhibition in combination with Sorafenib has a synergistic effect on HCC 
progression in vitro as well as in vivo 
• Cdk5 inhibition interferes with the Sorafenib-induced compensatory activation of growth 
factor receptors  
Importantly, Cdk5 inhibition was revealed to exert a mode of action that is different from 
classical growth factor receptor inhibitors as: 
• Cdk5 inhibition interferes with intracellular trafficking  
 
• Cdk5 inhibition therefore offers a comprehensive approach to globally block the 
activation of growth factor receptors in general 
 
What is the impact of our findings on clinical practice in the foreseeable future? 
 
• Cdk5 inhibition is a ground-breaking and valuable strategy to prevent Sorafenib 
treatment escape.  
• As with Dinaciclib a clinically tested Cdk5 inhibitor is available, evaluating the 
combination of Sorafenib and Cdk5 inhibition to improve the therapeutic situation for 
advanced-stage HCC patients turns out to become realistic.   
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
REFERENCES
References 
 
72 
 
5 REFERENCES 
1 Llovet, J. M., Burroughs, A. & Bruix, J. Hepatocellular carcinoma. Lancet 362, 1907-
1917, doi:10.1016/S0140-6736(03)14964-1 (2003). 
2 Caldwell, S. & Park, S. H. The epidemiology of hepatocellular cancer: from the 
perspectives of public health problem to tumor biology. J Gastroenterol 44 Suppl 19, 
96-101, doi:10.1007/s00535-008-2258-6 (2009). 
3 Alazawi, W., Cunningham, M., Dearden, J. & Foster, G. R. Systematic review: outcome 
of compensated cirrhosis due to chronic hepatitis C infection. Aliment Pharmacol Ther 
32, 344-355, doi:10.1111/j.1365-2036.2010.04370.x (2010). 
4 Sherman, M. Hepatocellular carcinoma: epidemiology, surveillance, and diagnosis. 
Semin Liver Dis 30, 3-16, doi:10.1055/s-0030-1247128 (2010). 
5 El-Serag, H. B. Hepatocellular carcinoma. N Engl J Med 365, 1118-1127, 
doi:10.1056/NEJMra1001683 (2011). 
6 El-Serag, H. B. Epidemiology of viral hepatitis and hepatocellular carcinoma. 
Gastroenterology 142, 1264-1273 e1261, doi:10.1053/j.gastro.2011.12.061 (2012). 
7 Inokawa, Y. et al. Molecular alterations in the carcinogenesis and progression of 
hepatocellular carcinoma: Tumor factors and background liver factors. Oncol Lett 12, 
3662-3668, doi:10.3892/ol.2016.5141 (2016). 
8 Hsu, H., Peng, S., Lai, P., Chu, J. & Lee, P. Mutations of p53 gene in hepatocellular-
carcinoma (hcc) correlate with tumor progression and patient prognosis - a study of 
138 patients with unifocal hcc. Int J Oncol 4, 1341-1347 (1994). 
9 Giles, R. H., van Es, J. H. & Clevers, H. Caught up in a Wnt storm: Wnt signaling in 
cancer. Biochim Biophys Acta 1653, 1-24 (2003). 
10 Kim, M. et al. Functional interaction between Wnt3 and Frizzled-7 leads to activation of 
the Wnt/beta-catenin signaling pathway in hepatocellular carcinoma cells. J Hepatol 
48, 780-791, doi:10.1016/j.jhep.2007.12.020 (2008). 
11 Llovet, J. M., Bru, C. & Bruix, J. Prognosis of hepatocellular carcinoma: the BCLC 
staging classification. Semin Liver Dis 19, 329-338, doi:10.1055/s-2007-1007122 
(1999). 
12 Pugh, R. N., Murray-Lyon, I. M., Dawson, J. L., Pietroni, M. C. & Williams, R. 
Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 60, 646-
649 (1973). 
13 Lin, S., Hoffmann, K. & Schemmer, P. Treatment of hepatocellular carcinoma: a 
systematic review. Liver Cancer 1, 144-158, doi:10.1159/000343828 (2012). 
14 Bruix, J., Sherman, M. & American Association for the Study of Liver, D. Management 
of hepatocellular carcinoma: an update. Hepatology 53, 1020-1022, 
doi:10.1002/hep.24199 (2011). 
15 Llovet, J. M. et al. Liver transplantation for small hepatocellular carcinoma: the tumor-
node-metastasis classification does not have prognostic power. Hepatology 27, 1572-
1577, doi:10.1002/hep.510270616 (1998). 
16 Han, K. & Kim, J. H. Transarterial chemoembolization in hepatocellular carcinoma 
treatment: Barcelona clinic liver cancer staging system. World J Gastroenterol 21, 
10327-10335, doi:10.3748/wjg.v21.i36.10327 (2015). 
17 El-Serag, H. B., Marrero, J. A., Rudolph, L. & Reddy, K. R. Diagnosis and treatment of 
hepatocellular carcinoma. Gastroenterology 134, 1752-1763, 
doi:10.1053/j.gastro.2008.02.090 (2008). 
18 Asghar, U. & Meyer, T. Are there opportunities for chemotherapy in the treatment of 
hepatocellular cancer? J Hepatol 56, 686-695, doi:10.1016/j.jhep.2011.07.031 (2012). 
19 Llovet, J. M. et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359, 
378-390, doi:10.1056/NEJMoa0708857 (2008). 
20 Forner, A., Gilabert, M., Bruix, J. & Raoul, J. L. Treatment of intermediate-stage 
hepatocellular carcinoma. Nat Rev Clin Oncol 11, 525-535, 
doi:10.1038/nrclinonc.2014.122 (2014). 
References 
 
73 
 
21 Abdel-Rahman, O. & Fouad, M. Sorafenib-based combination as a first line treatment 
for advanced hepatocellular carcinoma: a systematic review of the literature. Crit Rev 
Oncol Hematol 91, 1-8, doi:10.1016/j.critrevonc.2013.12.013 (2014). 
22 Adnane, L., Trail, P. A., Taylor, I. & Wilhelm, S. M. Sorafenib (BAY 43-9006, Nexavar), 
a dual-action inhibitor that targets RAF/MEK/ERK pathway in tumor cells and tyrosine 
kinases VEGFR/PDGFR in tumor vasculature. Methods Enzymol 407, 597-612, 
doi:10.1016/S0076-6879(05)07047-3 (2006). 
23 Wilhelm, S. M. et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and 
targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor 
progression and angiogenesis. Cancer Res 64, 7099-7109, doi:10.1158/0008-
5472.CAN-04-1443 (2004). 
24 Cheng, A. L. et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region 
with advanced hepatocellular carcinoma: a phase III randomised, double-blind, 
placebo-controlled trial. Lancet Oncol 10, 25-34, doi:10.1016/S1470-2045(08)70285-7 
(2009). 
25 Doyle, A. et al. Sorafenib in the treatment of hepatocellular carcinoma: a multi-centre 
real-world study. Scand J Gastroenterol 51, 979-985, 
doi:10.3109/00365521.2016.1166518 (2016). 
26 Ehrlich, S. M. et al. Targeting cyclin dependent kinase 5 in hepatocellular carcinoma--
A novel therapeutic approach. J Hepatol 63, 102-113, doi:10.1016/j.jhep.2015.01.031 
(2015). 
27 Malumbres, M. & Barbacid, M. Mammalian cyclin-dependent kinases. Trends Biochem 
Sci 30, 630-641, doi:10.1016/j.tibs.2005.09.005 (2005). 
28 Dhavan, R. & Tsai, L. H. A decade of CDK5. Nat Rev Mol Cell Biol 2, 749-759, 
doi:10.1038/35096019 (2001). 
29 Lew, J., Beaudette, K., Litwin, C. M. & Wang, J. H. Purification and characterization of 
a novel proline-directed protein kinase from bovine brain. J Biol Chem 267, 13383-
13390 (1992). 
30 Liebl, J., Furst, R., Vollmar, A. M. & Zahler, S. Twice switched at birth: cell cycle-
independent roles of the "neuron-specific" cyclin-dependent kinase 5 (Cdk5) in non-
neuronal cells. Cell Signal 23, 1698-1707, doi:10.1016/j.cellsig.2011.06.020 (2011). 
31 Hirasawa, M. et al. Perinatal abrogation of Cdk5 expression in brain results in neuronal 
migration defects. Proc Natl Acad Sci U S A 101, 6249-6254, 
doi:10.1073/pnas.0307322101 (2004). 
32 Chergui, K., Svenningsson, P. & Greengard, P. Cyclin-dependent kinase 5 regulates 
dopaminergic and glutamatergic transmission in the striatum. Proc Natl Acad Sci U S 
A 101, 2191-2196, doi:10.1073/pnas.0308652100 (2004). 
33 Cheung, Z. H. & Ip, N. Y. Cdk5: a multifaceted kinase in neurodegenerative diseases. 
Trends Cell Biol 22, 169-175, doi:10.1016/j.tcb.2011.11.003 (2012). 
34 Noble, W. et al. Cdk5 is a key factor in tau aggregation and tangle formation in vivo. 
Neuron 38, 555-565 (2003). 
35 Zhang, P. et al. Cdk5-Dependent Activation of Neuronal Inflammasomes in Parkinson's 
Disease. Mov Disord 31, 366-376, doi:10.1002/mds.26488 (2016). 
36 Wong, A. S. et al. Cdk5-mediated phosphorylation of endophilin B1 is required for 
induced autophagy in models of Parkinson's disease. Nat Cell Biol 13, 568-579, 
doi:10.1038/ncb2217 (2011). 
37 Ko, J. et al. p35 and p39 are essential for cyclin-dependent kinase 5 function during 
neurodevelopment. J Neurosci 21, 6758-6771 (2001). 
38 Humbert, S., Dhavan, R. & Tsai, L. p39 activates cdk5 in neurons, and is associated 
with the actin cytoskeleton. J Cell Sci 113 ( Pt 6), 975-983 (2000). 
39 Zukerberg, L. R. et al. Cables links Cdk5 and c-Abl and facilitates Cdk5 tyrosine 
phosphorylation, kinase upregulation, and neurite outgrowth. Neuron 26, 633-646 
(2000). 
40 Sasaki, Y. et al. Fyn and Cdk5 mediate semaphorin-3A signaling, which is involved in 
regulation of dendrite orientation in cerebral cortex. Neuron 35, 907-920 (2002). 
References 
 
74 
 
41 Kobayashi, H. et al. Phosphorylation of cyclin-dependent kinase 5 (Cdk5) at Tyr-15 is 
inhibited by Cdk5 activators and does not contribute to the activation of Cdk5. J Biol 
Chem 289, 19627-19636, doi:10.1074/jbc.M113.501148 (2014). 
42 Kimura, T., Ishiguro, K. & Hisanaga, S. Physiological and pathological phosphorylation 
of tau by Cdk5. Front Mol Neurosci 7, 65, doi:10.3389/fnmol.2014.00065 (2014). 
43 Arif, A. Extraneuronal activities and regulatory mechanisms of the atypical cyclin-
dependent kinase Cdk5. Biochem Pharmacol 84, 985-993, 
doi:10.1016/j.bcp.2012.06.027 (2012). 
44 Tarricone, C. et al. Structure and regulation of the CDK5-p25(nck5a) complex. Mol Cell 
8, 657-669 (2001). 
45 Pozo, K. & Bibb, J. A. The Emerging Role of Cdk5 in Cancer. Trends Cancer 2, 606-
618, doi:10.1016/j.trecan.2016.09.001 (2016). 
46 Choi, H. S. et al. Single-nucleotide polymorphisms in the promoter of the CDK5 gene 
and lung cancer risk in a Korean population. J Hum Genet 54, 298-303, 
doi:10.1038/jhg.2009.29 (2009). 
47 Kibel, A. S. et al. Genetic variants in cell cycle control pathway confer susceptibility to 
aggressive prostate carcinoma. Prostate 76, 479-490, doi:10.1002/pros.23139 (2016). 
48 Liu, J. L. et al. Expression of CDK5/p35 in resected patients with non-small cell lung 
cancer: relation to prognosis. Med Oncol 28, 673-678, doi:10.1007/s12032-010-9510-
7 (2011). 
49 Catania, A. et al. Expression and localization of cyclin-dependent kinase 5 in apoptotic 
human glioma cells. Neuro Oncol 3, 89-98 (2001). 
50 Zhang, X. et al. Aberrant expression of CDK5 infers poor outcomes for nasopharyngeal 
carcinoma patients. Int J Clin Exp Pathol 8, 8066-8074 (2015). 
51 Chiker, S. et al. Cdk5 promotes DNA replication stress checkpoint activation through 
RPA-32 phosphorylation, and impacts on metastasis free survival in breast cancer 
patients. Cell Cycle 14, 3066-3078, doi:10.1080/15384101.2015.1078020 (2015). 
52 Futatsugi, A. et al. Cyclin-dependent kinase 5 regulates E2F transcription factor 
through phosphorylation of Rb protein in neurons. Cell Cycle 11, 1603-1610, 
doi:10.4161/cc.20009 (2012). 
53 Pozo, K. et al. The role of Cdk5 in neuroendocrine thyroid cancer. Cancer Cell 24, 499-
511, doi:10.1016/j.ccr.2013.08.027 (2013). 
54 Hsu, F. N. et al. Cyclin-dependent kinase 5 modulates STAT3 and androgen receptor 
activation through phosphorylation of Ser(7)(2)(7) on STAT3 in prostate cancer cells. 
Am J Physiol Endocrinol Metab 305, E975-986, doi:10.1152/ajpendo.00615.2012 
(2013). 
55 Lindqvist, J. et al. Cyclin-dependent kinase 5 acts as a critical determinant of AKT-
dependent proliferation and regulates differential gene expression by the androgen 
receptor in prostate cancer cells. Mol Biol Cell 26, 1971-1984, doi:10.1091/mbc.E14-
12-1634 (2015). 
56 Sharma, M. R., Tuszynski, G. P. & Sharma, M. C. Angiostatin-induced inhibition of 
endothelial cell proliferation/apoptosis is associated with the down-regulation of cell 
cycle regulatory protein cdk5. J Cell Biochem 91, 398-409, doi:10.1002/jcb.10762 
(2004). 
57 Liebl, J. et al. Cyclin-dependent kinase 5 regulates endothelial cell migration and 
angiogenesis. J Biol Chem 285, 35932-35943, doi:10.1074/jbc.M110.126177 (2010). 
58 Merk, H. et al. Inhibition of endothelial Cdk5 reduces tumor growth by promoting non-
productive angiogenesis. Oncotarget 7, 6088-6104, doi:10.18632/oncotarget.6842 
(2016). 
59 Malumbres, M. & Barbacid, M. To cycle or not to cycle: a critical decision in cancer. Nat 
Rev Cancer 1, 222-231, doi:10.1038/35106065 (2001). 
60 Malumbres, M. & Barbacid, M. Cell cycle, CDKs and cancer: a changing paradigm. Nat 
Rev Cancer 9, 153-166, doi:10.1038/nrc2602 (2009). 
61 Bach, S. et al. Roscovitine targets, protein kinases and pyridoxal kinase. J Biol Chem 
280, 31208-31219, doi:10.1074/jbc.M500806200 (2005). 
References 
 
75 
 
62 Weishaupt, J. H. et al. Inhibition of CDK5 is protective in necrotic and apoptotic 
paradigms of neuronal cell death and prevents mitochondrial dysfunction. Mol Cell 
Neurosci 24, 489-502 (2003). 
63 Helal, C. J. et al. Potent and cellularly active 4-aminoimidazole inhibitors of cyclin-
dependent kinase 5/p25 for the treatment of Alzheimer's disease. Bioorg Med Chem 
Lett 19, 5703-5707, doi:10.1016/j.bmcl.2009.08.019 (2009). 
64 Parry, D. et al. Dinaciclib (SCH 727965), a novel and potent cyclin-dependent kinase 
inhibitor. Mol Cancer Ther 9, 2344-2353, doi:10.1158/1535-7163.MCT-10-0324 (2010). 
65 Ran, F. A. et al. Genome engineering using the CRISPR-Cas9 system. Nat Protoc 8, 
2281-2308, doi:10.1038/nprot.2013.143 (2013). 
66 Haeussler, M. et al. Evaluation of off-target and on-target scoring algorithms and 
integration into the guide RNA selection tool CRISPOR. Genome Biol 17, 148, 
doi:10.1186/s13059-016-1012-2 (2016). 
67 Slaymaker, I. M. et al. Rationally engineered Cas9 nucleases with improved specificity. 
Science 351, 84-88, doi:10.1126/science.aad5227 (2016). 
68 Laemmli, U. K. Cleavage of structural proteins during the assembly of the head of 
bacteriophage T4. Nature 227, 680-685 (1970). 
69 Kurien, B. T. & Scofield, R. H. Protein blotting: a review. J Immunol Methods 274, 1-15 
(2003). 
70 Fleige, S. et al. Comparison of relative mRNA quantification models and the impact of 
RNA integrity in quantitative real-time RT-PCR. Biotechnol Lett 28, 1601-1613, 
doi:10.1007/s10529-006-9127-2 (2006). 
71 Berenbaum, M. C. What is synergy? Pharmacol Rev 41, 93-141 (1989). 
72 Nicoletti, I., Migliorati, G., Pagliacci, M. C., Grignani, F. & Riccardi, C. A rapid and 
simple method for measuring thymocyte apoptosis by propidium iodide staining and 
flow cytometry. J Immunol Methods 139, 271-279 (1991). 
73 Remmele, W. & Stegner, H. E. [Recommendation for uniform definition of an 
immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-
ICA) in breast cancer tissue]. Pathologe 8, 138-140 (1987). 
74 Weitensteiner, S. B. et al. Trisubstituted pyrazolopyrimidines as novel angiogenesis 
inhibitors. PLoS One 8, e54607, doi:10.1371/journal.pone.0054607 (2013). 
75 Foucquier, J. & Guedj, M. Analysis of drug combinations: current methodological 
landscape. Pharmacol Res Perspect 3, e00149, doi:10.1002/prp2.149 (2015). 
76 McDaniel, K. et al. Lin28 and let-7: roles and regulation in liver diseases. Am J Physiol 
Gastrointest Liver Physiol 310, G757-765, doi:10.1152/ajpgi.00080.2016 (2016). 
77 Ito, Y. et al. Expression and clinical significance of erb-B receptor family in 
hepatocellular carcinoma. Br J Cancer 84, 1377-1383, doi:10.1054/bjoc.2000.1580 
(2001). 
78 Blivet-Van Eggelpoel, M. J. et al. Epidermal growth factor receptor and HER-3 restrict 
cell response to sorafenib in hepatocellular carcinoma cells. J Hepatol 57, 108-115, 
doi:10.1016/j.jhep.2012.02.019 (2012). 
79 Firtina Karagonlar, Z., Koc, D., Iscan, E., Erdal, E. & Atabey, N. Elevated hepatocyte 
growth factor expression as an autocrine c-Met activation mechanism in acquired 
resistance to sorafenib in hepatocellular carcinoma cells. Cancer Sci 107, 407-416, 
doi:10.1111/cas.12891 (2016). 
80 Tovar, V. et al. Tumour initiating cells and IGF/FGF signalling contribute to sorafenib 
resistance in hepatocellular carcinoma. Gut 66, 530-540, doi:10.1136/gutjnl-2015-
309501 (2017). 
81 Sigismund, S. et al. Endocytosis and signaling: cell logistics shape the eukaryotic cell 
plan. Physiol Rev 92, 273-366, doi:10.1152/physrev.00005.2011 (2012). 
82 Giordano, S. & Columbano, A. Met as a therapeutic target in HCC: facts and hopes. J 
Hepatol 60, 442-452, doi:10.1016/j.jhep.2013.09.009 (2014). 
83 Llovet, J. M. et al. Design and endpoints of clinical trials in hepatocellular carcinoma. J 
Natl Cancer Inst 100, 698-711, doi:10.1093/jnci/djn134 (2008). 
References 
 
76 
 
84 Hsu, C. H. et al. Phase II study of combining sorafenib with metronomic tegafur/uracil 
for advanced hepatocellular carcinoma. J Hepatol 53, 126-131, 
doi:10.1016/j.jhep.2010.01.035 (2010). 
85 Petrini, I. et al. Phase II trial of sorafenib in combination with 5-fluorouracil infusion in 
advanced hepatocellular carcinoma. Cancer Chemother Pharmacol 69, 773-780, 
doi:10.1007/s00280-011-1753-2 (2012). 
86 Abou-Alfa, G. K. et al. Doxorubicin plus sorafenib vs doxorubicin alone in patients with 
advanced hepatocellular carcinoma: a randomized trial. JAMA 304, 2154-2160, 
doi:10.1001/jama.2010.1672 (2010). 
87 Richly, H. et al. Combination of sorafenib and doxorubicin in patients with advanced 
hepatocellular carcinoma: results from a phase I extension trial. Eur J Cancer 45, 579-
587, doi:10.1016/j.ejca.2008.10.039 (2009). 
88 Gomez-Martin, C. et al. Efficacy and safety of sorafenib in combination with mammalian 
target of rapamycin inhibitors for recurrent hepatocellular carcinoma after liver 
transplantation. Liver Transpl 18, 45-52, doi:10.1002/lt.22434 (2012). 
89 Finn, R. S. et al. Phase I study investigating everolimus combined with sorafenib in 
patients with advanced hepatocellular carcinoma. J Hepatol 59, 1271-1277, 
doi:10.1016/j.jhep.2013.07.029 (2013). 
90 Cheng, A. L. et al. Sunitinib versus sorafenib in advanced hepatocellular cancer: results 
of a randomized phase III trial. J Clin Oncol 31, 4067-4075, 
doi:10.1200/JCO.2012.45.8372 (2013). 
91 Johnson, P. J. et al. Brivanib versus sorafenib as first-line therapy in patients with 
unresectable, advanced hepatocellular carcinoma: results from the randomized phase 
III BRISK-FL study. J Clin Oncol 31, 3517-3524, doi:10.1200/JCO.2012.48.4410 
(2013). 
92 Cainap, C. et al. Linifanib versus Sorafenib in patients with advanced hepatocellular 
carcinoma: results of a randomized phase III trial. J Clin Oncol 33, 172-179, 
doi:10.1200/JCO.2013.54.3298 (2015). 
93 Llovet, J. M. et al. Brivanib in patients with advanced hepatocellular carcinoma who 
were intolerant to sorafenib or for whom sorafenib failed: results from the randomized 
phase III BRISK-PS study. J Clin Oncol 31, 3509-3516, doi:10.1200/JCO.2012.47.3009 
(2013). 
94 Zhu, A. X. et al. Effect of everolimus on survival in advanced hepatocellular carcinoma 
after failure of sorafenib: the EVOLVE-1 randomized clinical trial. JAMA 312, 57-67, 
doi:10.1001/jama.2014.7189 (2014). 
95 Zhu, A. X. et al. Ramucirumab versus placebo as second-line treatment in patients with 
advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): 
a randomised, double-blind, multicentre, phase 3 trial. Lancet Oncol 16, 859-870, 
doi:10.1016/S1470-2045(15)00050-9 (2015). 
96 Bruix, J. et al. Regorafenib for patients with hepatocellular carcinoma who progressed 
on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, 
phase 3 trial. Lancet 389, 56-66, doi:10.1016/S0140-6736(16)32453-9 (2017). 
97 Ikeda, K. et al. Phase 2 study of lenvatinib in patients with advanced hepatocellular 
carcinoma. J Gastroenterol 52, 512-519, doi:10.1007/s00535-016-1263-4 (2017). 
98 Kudo, M. et al. Lenvatinib versus sorafenib in first-line treatment of patients with 
unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. 
Lancet, doi:10.1016/S0140-6736(18)30207-1 (2018). 
99 Calderaro, J. et al. Programmed death ligand 1 expression in hepatocellular carcinoma: 
Relationship With clinical and pathological features. Hepatology 64, 2038-2046, 
doi:10.1002/hep.28710 (2016). 
100 El-Khoueiry, A. B. et al. Nivolumab in patients with advanced hepatocellular carcinoma 
(CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and 
expansion trial. Lancet 389, 2492-2502, doi:10.1016/S0140-6736(17)31046-2 (2017). 
101 Engelman, J. A. et al. MET amplification leads to gefitinib resistance in lung cancer by 
activating ERBB3 signaling. Science 316, 1039-1043, doi:10.1126/science.1141478 
(2007). 
References 
 
77 
 
102 Gao, J. J., Shi, Z. Y., Xia, J. F., Inagaki, Y. & Tang, W. Sorafenib-based combined 
molecule targeting in treatment of hepatocellular carcinoma. World J Gastroenterol 21, 
12059-12070, doi:10.3748/wjg.v21.i42.12059 (2015). 
103 Huynh, H. et al. AZD6244 enhances the anti-tumor activity of sorafenib in ectopic and 
orthotopic models of human hepatocellular carcinoma (HCC). J Hepatol 52, 79-87, 
doi:10.1016/j.jhep.2009.10.008 (2010). 
104 Schmieder, R. et al. Allosteric MEK1/2 inhibitor refametinib (BAY 86-9766) in 
combination with sorafenib exhibits antitumor activity in preclinical murine and rat 
models of hepatocellular carcinoma. Neoplasia 15, 1161-1171 (2013). 
105 Lim, H. Y. et al. A phase II study of the efficacy and safety of the combination therapy 
of the MEK inhibitor refametinib (BAY 86-9766) plus sorafenib for Asian patients with 
unresectable hepatocellular carcinoma. Clin Cancer Res 20, 5976-5985, 
doi:10.1158/1078-0432.CCR-13-3445 (2014). 
106 Rudalska, R. et al. In vivo RNAi screening identifies a mechanism of sorafenib 
resistance in liver cancer. Nat Med 20, 1138-1146, doi:10.1038/nm.3679 (2014). 
107 Villanueva, A. et al. Pivotal role of mTOR signaling in hepatocellular carcinoma. 
Gastroenterology 135, 1972-1983, 1983 e1971-1911, 
doi:10.1053/j.gastro.2008.08.008 (2008). 
108 Zhu, A. X. et al. Phase 1/2 study of everolimus in advanced hepatocellular carcinoma. 
Cancer 117, 5094-5102, doi:10.1002/cncr.26165 (2011). 
109 Koeberle, D. et al. Sorafenib with or without everolimus in patients with advanced 
hepatocellular carcinoma (HCC): a randomized multicenter, multinational phase II trial 
(SAKK 77/08 and SASL 29). Ann Oncol 27, 856-861, doi:10.1093/annonc/mdw054 
(2016). 
110 Berasain, C. & Avila, M. A. The EGFR signalling system in the liver: from 
hepatoprotection to hepatocarcinogenesis. J Gastroenterol 49, 9-23, 
doi:10.1007/s00535-013-0907-x (2014). 
111 Carracedo, A. et al. Inhibition of mTORC1 leads to MAPK pathway activation through 
a PI3K-dependent feedback loop in human cancer. J Clin Invest 118, 3065-3074, 
doi:10.1172/JCI34739 (2008). 
112 Gedaly, R. et al. PI-103 and sorafenib inhibit hepatocellular carcinoma cell proliferation 
by blocking Ras/Raf/MAPK and PI3K/AKT/mTOR pathways. Anticancer Res 30, 4951-
4958 (2010). 
113 Masuda, M. et al. Alternative mammalian target of rapamycin (mTOR) signal activation 
in sorafenib-resistant hepatocellular carcinoma cells revealed by array-based pathway 
profiling. Mol Cell Proteomics 13, 1429-1438, doi:10.1074/mcp.M113.033845 (2014). 
114 Rose, A. et al. Stimulatory effects of the multi-kinase inhibitor sorafenib on human 
bladder cancer cells. Br J Pharmacol 160, 1690-1698, doi:10.1111/j.1476-
5381.2010.00838.x (2010). 
115 Wang, H. et al. Activation of phosphatidylinositol 3-kinase/Akt signaling mediates 
sorafenib-induced invasion and metastasis in hepatocellular carcinoma. Oncol Rep 32, 
1465-1472, doi:10.3892/or.2014.3352 (2014). 
116 de Larco, J. E. & Todaro, G. J. Epithelioid and fibroblastic rat kidney cell clones: 
epidermal growth factor (EGF) receptors and the effect of mouse sarcoma virus 
transformation. J Cell Physiol 94, 335-342, doi:10.1002/jcp.1040940311 (1978). 
117 Yarden, Y. & Sliwkowski, M. X. Untangling the ErbB signalling network. Nat Rev Mol 
Cell Biol 2, 127-137, doi:10.1038/35052073 (2001). 
118 Yewale, C., Baradia, D., Vhora, I., Patil, S. & Misra, A. Epidermal growth factor receptor 
targeting in cancer: a review of trends and strategies. Biomaterials 34, 8690-8707, 
doi:10.1016/j.biomaterials.2013.07.100 (2013). 
119 Kira, S. et al. Expression of transforming growth factor alpha and epidermal growth 
factor receptor in human hepatocellular carcinoma. Liver 17, 177-182 (1997). 
120 Daveau, M. et al. Hepatocyte growth factor, transforming growth factor alpha, and their 
receptors as combined markers of prognosis in hepatocellular carcinoma. Mol Carcinog 
36, 130-141, doi:10.1002/mc.10103 (2003). 
References 
 
78 
 
121 Komposch, K. & Sibilia, M. EGFR Signaling in Liver Diseases. Int J Mol Sci 17, 
doi:10.3390/ijms17010030 (2015). 
122 Huether, A., Hopfner, M., Baradari, V., Schuppan, D. & Scherubl, H. EGFR blockade 
by cetuximab alone or as combination therapy for growth control of hepatocellular 
cancer. Biochem Pharmacol 70, 1568-1578, doi:10.1016/j.bcp.2005.09.007 (2005). 
123 Huether, A., Hopfner, M., Sutter, A. P., Schuppan, D. & Scherubl, H. Erlotinib induces 
cell cycle arrest and apoptosis in hepatocellular cancer cells and enhances 
chemosensitivity towards cytostatics. J Hepatol 43, 661-669, 
doi:10.1016/j.jhep.2005.02.040 (2005). 
124 Okano, J., Matsumoto, K., Nagahara, T. & Murawaki, Y. Gefitinib and the modulation 
of the signaling pathways downstream of epidermal growth factor receptor in human 
liver cancer cells. J Gastroenterol 41, 166-176, doi:10.1007/s00535-005-1736-3 
(2006). 
125 Huether, A. et al. Signaling pathways involved in the inhibition of epidermal growth 
factor receptor by erlotinib in hepatocellular cancer. World J Gastroenterol 12, 5160-
5167 (2006). 
126 Fuchs, B. C. et al. Epidermal growth factor receptor inhibition attenuates liver fibrosis 
and development of hepatocellular carcinoma. Hepatology 59, 1577-1590, 
doi:10.1002/hep.26898 (2014). 
127 Matsuo, M., Sakurai, H. & Saiki, I. ZD1839, a selective epidermal growth factor receptor 
tyrosine kinase inhibitor, shows antimetastatic activity using a hepatocellular carcinoma 
model. Mol Cancer Ther 2, 557-561 (2003). 
128 Zhu, B. D. et al. Antitumor effect of Gefitinib, an epidermal growth factor receptor 
tyrosine kinase inhibitor, combined with cytotoxic agent on murine hepatocellular 
carcinoma. World J Gastroenterol 11, 1382-1386 (2005). 
129 Baselga, J. & Arteaga, C. L. Critical update and emerging trends in epidermal growth 
factor receptor targeting in cancer. J Clin Oncol 23, 2445-2459, 
doi:10.1200/JCO.2005.11.890 (2005). 
130 Marshall, J. Clinical implications of the mechanism of epidermal growth factor receptor 
inhibitors. Cancer 107, 1207-1218, doi:10.1002/cncr.22133 (2006). 
131 Ramanathan, R. K. et al. A phase II study of lapatinib in patients with advanced biliary 
tree and hepatocellular cancer. Cancer Chemother Pharmacol 64, 777-783, 
doi:10.1007/s00280-009-0927-7 (2009). 
132 Llovet, J. M. & Bruix, J. Molecular targeted therapies in hepatocellular carcinoma. 
Hepatology 48, 1312-1327, doi:10.1002/hep.22506 (2008). 
133 Thomas, M. B. et al. Phase 2 study of erlotinib in patients with unresectable 
hepatocellular carcinoma. Cancer 110, 1059-1067, doi:10.1002/cncr.22886 (2007). 
134 Zhu, A. X. et al. Phase 2 study of cetuximab in patients with advanced hepatocellular 
carcinoma. Cancer 110, 581-589, doi:10.1002/cncr.22829 (2007). 
135 Asnacios, A. et al. Gemcitabine plus oxaliplatin (GEMOX) combined with cetuximab in 
patients with progressive advanced stage hepatocellular carcinoma: results of a 
multicenter phase 2 study. Cancer 112, 2733-2739, doi:10.1002/cncr.23489 (2008). 
136 Hsu, C. H. et al. Bevacizumab with erlotinib as first-line therapy in Asian patients with 
advanced hepatocellular carcinoma: a multicenter phase II study. Oncology 85, 44-52, 
doi:10.1159/000350841 (2013). 
137 Zhu, A. X. et al. SEARCH: a phase III, randomized, double-blind, placebo-controlled 
trial of sorafenib plus erlotinib in patients with advanced hepatocellular carcinoma. J 
Clin Oncol 33, 559-566, doi:10.1200/JCO.2013.53.7746 (2015). 
138 Sakata, H. et al. Hepatocyte growth factor/scatter factor overexpression induces 
growth, abnormal development, and tumor formation in transgenic mouse livers. Cell 
Growth Differ 7, 1513-1523 (1996). 
139 Wang, R., Ferrell, L. D., Faouzi, S., Maher, J. J. & Bishop, J. M. Activation of the Met 
receptor by cell attachment induces and sustains hepatocellular carcinomas in 
transgenic mice. J Cell Biol 153, 1023-1034 (2001). 
140 Jo, M. et al. Cross-talk between epidermal growth factor receptor and c-Met signal 
pathways in transformed cells. J Biol Chem 275, 8806-8811 (2000). 
References 
 
79 
 
141 Desbois-Mouthon, C. et al. Insulin-like growth factor-1 receptor inhibition induces a 
resistance mechanism via the epidermal growth factor receptor/HER3/AKT signaling 
pathway: rational basis for cotargeting insulin-like growth factor-1 receptor and 
epidermal growth factor receptor in hepatocellular carcinoma. Clin Cancer Res 15, 
5445-5456, doi:10.1158/1078-0432.CCR-08-2980 (2009). 
142 Desbois-Mouthon, C. et al. Impact of IGF-1R/EGFR cross-talks on hepatoma cell 
sensitivity to gefitinib. Int J Cancer 119, 2557-2566, doi:10.1002/ijc.22221 (2006). 
143 Lanzetti, L. & Di Fiore, P. P. Endocytosis and cancer: an 'insider' network with 
dangerous liaisons. Traffic 9, 2011-2021, doi:10.1111/j.1600-0854.2008.00816.x 
(2008). 
144 Rink, J., Ghigo, E., Kalaidzidis, Y. & Zerial, M. Rab conversion as a mechanism of 
progression from early to late endosomes. Cell 122, 735-749, 
doi:10.1016/j.cell.2005.06.043 (2005). 
145 Stenmark, H. Rab GTPases as coordinators of vesicle traffic. Nat Rev Mol Cell Biol 10, 
513-525, doi:10.1038/nrm2728 (2009). 
146 Porther, N. & Barbieri, M. A. The role of endocytic Rab GTPases in regulation of growth 
factor signaling and the migration and invasion of tumor cells. Small GTPases 6, 135-
144, doi:10.1080/21541248.2015.1050152 (2015). 
147 Mellman, I. & Yarden, Y. Endocytosis and cancer. Cold Spring Harb Perspect Biol 5, 
a016949, doi:10.1101/cshperspect.a016949 (2013). 
148 Mosesson, Y., Mills, G. B. & Yarden, Y. Derailed endocytosis: an emerging feature of 
cancer. Nat Rev Cancer 8, 835-850, doi:10.1038/nrc2521 (2008). 
149 Ebner, R. & Derynck, R. Epidermal growth factor and transforming growth factor-alpha: 
differential intracellular routing and processing of ligand-receptor complexes. Cell 
Regul 2, 599-612 (1991). 
150 Huangfu, W. C. & Fuchs, S. Y. Ubiquitination-dependent regulation of signaling 
receptors in cancer. Genes Cancer 1, 725-734, doi:10.1177/1947601910382901 
(2010). 
151 Grandal, M. V. et al. EGFRvIII escapes down-regulation due to impaired internalization 
and sorting to lysosomes. Carcinogenesis 28, 1408-1417, doi:10.1093/carcin/bgm058 
(2007). 
152 Katzmann, D. J., Odorizzi, G. & Emr, S. D. Receptor downregulation and multivesicular-
body sorting. Nat Rev Mol Cell Biol 3, 893-905, doi:10.1038/nrm973 (2002). 
153 Doyotte, A., Russell, M. R., Hopkins, C. R. & Woodman, P. G. Depletion of TSG101 
forms a mammalian "Class E" compartment: a multicisternal early endosome with 
multiple sorting defects. J Cell Sci 118, 3003-3017, doi:10.1242/jcs.02421 (2005). 
154 Bache, K. G. et al. The ESCRT-III subunit hVps24 is required for degradation but not 
silencing of the epidermal growth factor receptor. Mol Biol Cell 17, 2513-2523, 
doi:10.1091/mbc.E05-10-0915 (2006). 
155 Paul, N. R., Jacquemet, G. & Caswell, P. T. Endocytic Trafficking of Integrins in Cell 
Migration. Curr Biol 25, R1092-1105, doi:10.1016/j.cub.2015.09.049 (2015). 
156 Seguin, L., Desgrosellier, J. S., Weis, S. M. & Cheresh, D. A. Integrins and cancer: 
regulators of cancer stemness, metastasis, and drug resistance. Trends Cell Biol 25, 
234-240, doi:10.1016/j.tcb.2014.12.006 (2015). 
157 Corallino, S., Malabarba, M. G., Zobel, M., Di Fiore, P. P. & Scita, G. Epithelial-to-
Mesenchymal Plasticity Harnesses Endocytic Circuitries. Front Oncol 5, 45, 
doi:10.3389/fonc.2015.00045 (2015). 
158 Wiedmann, R. M. et al. The V-ATPase-inhibitor archazolid abrogates tumor metastasis 
via inhibition of endocytic activation of the Rho-GTPase Rac1. Cancer Res 72, 5976-
5987, doi:10.1158/0008-5472.CAN-12-1772 (2012). 
159 Schneider, L. S. et al. Vacuolar-ATPase Inhibition Blocks Iron Metabolism to Mediate 
Therapeutic Effects in Breast Cancer. Cancer Res 75, 2863-2874, doi:10.1158/0008-
5472.CAN-14-2097 (2015). 
160 Merk, H. et al. Inhibition of the V-ATPase by Archazolid A: A New Strategy to Inhibit 
EMT. Mol Cancer Ther 16, 2329-2339, doi:10.1158/1535-7163.MCT-17-0129 (2017). 
References 
 
80 
 
161 Tan, T. C. et al. Cdk5 is essential for synaptic vesicle endocytosis. Nat Cell Biol 5, 701-
710, doi:10.1038/ncb1020 (2003). 
162 Tomizawa, K. et al. Cophosphorylation of amphiphysin I and dynamin I by Cdk5 
regulates clathrin-mediated endocytosis of synaptic vesicles. J Cell Biol 163, 813-824, 
doi:10.1083/jcb.200308110 (2003). 
163 Kawauchi, T. Cdk5 regulates multiple cellular events in neural development, function 
and disease. Dev Growth Differ 56, 335-348, doi:10.1111/dgd.12138 (2014). 
164 Furusawa, K. et al. Cdk5 Regulation of the GRAB-Mediated Rab8-Rab11 Cascade in 
Axon Outgrowth. J Neurosci 37, 790-806, doi:10.1523/JNEUROSCI.2197-16.2016 
(2017). 
165 Finn, R. S. et al. Palbociclib and Letrozole in Advanced Breast Cancer. N Engl J Med 
375, 1925-1936, doi:10.1056/NEJMoa1607303 (2016). 
166 Hortobagyi, G. N. et al. Ribociclib as First-Line Therapy for HR-Positive, Advanced 
Breast Cancer. N Engl J Med 375, 1738-1748, doi:10.1056/NEJMoa1609709 (2016). 
167 Goetz, M. P. et al. MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast 
Cancer. J Clin Oncol 35, 3638-3646, doi:10.1200/JCO.2017.75.6155 (2017). 
168 Bollard, J. et al. Palbociclib (PD-0332991), a selective CDK4/6 inhibitor, restricts 
tumour growth in preclinical models of hepatocellular carcinoma. Gut 66, 1286-1296, 
doi:10.1136/gutjnl-2016-312268 (2017). 
169 Contreras-Vallejos, E., Utreras, E. & Gonzalez-Billault, C. Going out of the brain: non-
nervous system physiological and pathological functions of Cdk5. Cell Signal 24, 44-
52, doi:10.1016/j.cellsig.2011.08.022 (2012). 
170 Shupp, A., Casimiro, M. C. & Pestell, R. G. Biological functions of CDK5 and potential 
CDK5 targeted clinical treatments. Oncotarget 8, 17373-17382, 
doi:10.18632/oncotarget.14538 (2017). 
171 Seftel, M. D. et al. The CDK inhibitor AT7519M in patients with relapsed or refractory 
chronic lymphocytic leukemia (CLL) and mantle cell lymphoma. A Phase II study of the 
Canadian Cancer Trials Group. Leuk Lymphoma 58, 1358-1365, 
doi:10.1080/10428194.2016.1239259 (2017). 
172 Ghia, P. et al. Efficacy and safety of dinaciclib vs ofatumumab in patients with 
relapsed/refractory chronic lymphocytic leukemia. Blood 129, 1876-1878, 
doi:10.1182/blood-2016-10-748210 (2017). 
173 Kumar, S. K. et al. Dinaciclib, a novel CDK inhibitor, demonstrates encouraging single-
agent activity in patients with relapsed multiple myeloma. Blood 125, 443-448, 
doi:10.1182/blood-2014-05-573741 (2015). 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
APPENDIX
Appendix 
 
82 
 
6 APPENDIX 
6.1 Supplementary Figures 
 
Supplementary Figure 1 - Proteomic analysis of Cdk5 knockdown cells treated with Sorafenib. 
(a) Table of proteins showing alterations of protein abundance (P-value < 0.05; log2-fold change > |0.6|) 
between nt and Cdk5 shRNA cells treated with Sorafenib together with their respective gene names, x-
fold changes (nt 5 µM Sorafenib vs. Cdk5 5 µM Sorafenib) and P-values. (b) Volcano Plot visualizing 
the protein hits given in a is shown. (c) Protein interaction map of protein hits given in a created with 
string-db.org. (protein-protein interaction enrichment P-value: 1.57*10-6). 
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Supplementary Figure 2 - qPCR analysis of targets from the proteomics screen. mRNA 
expression of selected proteins yielded from the proteomic analysis of untreated (a) or Sorafenib treated 
(b) nt (white bars) and Cdk5 (grey bars) shRNA HUH7 cells. 
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6.2 Supplementary Table 
Supplementary Table 1 - Correlation of EGFR staining with clinical parameters. Contingency 
tables correlating percentage of EGFR positive cells, EGFR staining intensity and EGFR IRS with r-
classification (R0: no residual tumor, R1: residual tumor, X: N/A) (a), frequency of recurrence (0: no 
tumor recurrence, 1: tumor recurrence) (b), cause of death (c), tumor stage (d) and tumor grading (e) 
are shown.  
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6.3 Abbreviations 
2-DG 2-deoxy-D-glucose 
ANOVA Analysis of variance between groups 
APS Ammonium persulfate 
AR Androgen receptor 
ATP Adenosine triphosphate 
BCLC Barcelona clinic liver cancer staging 
BSA Bovine serum albumin 
c-Abl c-Abelson 
Cdk5 Cyclin-dependent kinase 5 
CLL Chronic lymphatic leukemia 
CNS Central nervous system 
ConcA Concanamycin A 
CTCF Corrected total cell fluorescence 
DEN Diethylnitrosamine 
DMEM Dulbecco’s modified eagle medium 
DMSO Dimethylsulfoxide 
DNA Deoxyribonucleic acid 
DTT Dithiothreitol 
ECAR Extracellular acidification rate 
E. coli Escherichia coli 
EDTA Ethylendiaminetetraacetic acid 
EEA1 Early endosome antigen 
EGF Epidermal growth factor 
EGFR Epidermal growth factor receptor 
EMT Epithelial-to-mesenchymal transition 
Erk Extracellular signalling-regulated kinase 
ESCRT Endosomal sorting complex required for transport 
FACS Fluorescence activated cell sorter 
FCS Fetal calf serum 
FGF Fibroblast growth factor 
FLT3 FMS-like tyrosine kinase 3 
FS Fluorochrome solution 
GAP GTPase-activating proteins 
GDP Guanosine diphosphate 
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GEF Guanine nucleotide exchange factors 
GFP Green fluorescent protein 
GTP Guanosine triphosphate 
HBV Hepatitis B virus 
HCC Hepatocellular carcinoma 
HCV Hepatitis C virus 
HDAC Histone deacetylase 
HGF Hepatocyte growth factor 
HGFR Hepatocyte growth factor receptor 
HRP Horse radish peroxidase 
IGF Insulin-like growth factor 
IGF1R Insulin-like growth factor-1 receptor 
IRS Immunoreactive score 
JCBR Japanese collection of research bioresources 
KO Knock-Out 
MAPK Mitogen-activated protein kinase 
MCL Mantle cell lymphoma 
MEK MAPK/ERK kinase 
MOI Multiplicity of infection 
mRNA Messanger RNA 
MTC Medullary thyroid carcinoma 
mTOR Mammalian target of rapamycin 
MVB Multivesicluar body 
Na3VO4 Sodium orthovanadate 
NaF Sodium fluoride 
NMDA N-methyl-D-aspartate 
NSCLC Non-small cell lung cancer 
OCR Oxygen consumption rate 
PBS Phosphate buffered saline 
PD-1 Programmed cell death protein 1 
PDGFR Platlet derived growth factor receptor 
PI Propidium iodide 
PI3K Phosphatidylinositol-4,5-bisphosphate 3-kinase 
PMSF Phenylmethylsulfonyl fluoride 
PPI Protein-protein interaction 
PVDF Polyvinylidene difluoride 
Rb Retinoblastoma protein 
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RNA Ribonucleic acid 
rpm Revolutions per minute 
RT Room temperatur 
RT-qPCR Realt time- quantitative polymerase chain reaction 
SCID Severe combined immunodeficiancy 
SDS Sodium dodecyl sulfate 
SDS-PAGE SDS-polyacrylamide gel electrophoresis 
SEM Standard error of the mean 
sgRNA Single guide RNA 
shRNA Short hairpin ribonucleic acid 
Sora Sorafenib 
STAT3 Signal transducer and activator of transcription 3 
TACE Transarterial chemoembolization 
TBS-T Tris-buffered saline-Tween 20 
TEMED Tetramethylethylenediamine 
TGF-α Transforming growth factor alpha 
TMA Tissue microarray 
VEGFR Vascular endothelial growth factor receptor 
Wnt Wingless 
wt Wild-type 
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